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INTRODUCTION 
             Drug Delivery Systems (DDS) are a strategic tool for expanding markets/indications, 
extending product life cycles and generating opportunities. DDS make a significant 
contribution to global pharmaceutical sales through market segmentation, and are moving 
rapidly. Despite of tremendous advancements in drug delivery, the oral route remains the 
perfect route for the administration of therapeutic agents because of low cost of therapy, ease 
of administration, accurate dosage, self‐medication, pain avoidance, versatility, leading to 
high levels of patient compliance.  
            Tablets and capsules are the most popular dosage forms which have wide acceptance 
up to 50-60% of total dosage forms. Among all conventional dosage forms tablet is the most 
popular one till today because of ease of administration, compact in nature, easy to 
manufacture and it can deliver accurate dose. But the main drawback of solid dosage forms is 
the difficulty in swallowing which is referred as dysphagia in some patients particularly 
pediatric and geriatric patients. The dysphagia occurs in geriatric patients due to fear of 
choking, hand tremors and in paediatric patients due to underdeveloped muscular and 
nervous systems and in schizophrenic patients which leads to poor patient compliance. The 
difficulty of swallowing also occurs when water is not available, in diarrhoea, coughing 
during common cold, allergic conditions and bronchial infection and many other medical 
conditions including stroke, parkinson‟s disease, AIDS, thyroidectomy, head and neck 
radiation therapy and other neurological disorders including cerebral palsy and it is also 
applicable to people who are ill in bed and those
 
active working patients who are busy or 
travelling, especially those who have no access to water. Improved patient compliance has 
achieved enormous demand. Consequently demand for their technologies is also increasing 
many folds. It is always the aim of a scientist or a dosage form designer to enhance the safety 
of a drug molecule while maintaining its therapeutic efficacy. Recent advances in Novel Drug 
Delivery Systems (NDDS) aim for the same by formulating a dosage form, convenient to be 
administered so as to achieve better patient compliance. Pharmaceutical technologists have 
put in their best efforts to develop a Fast Dissolving Drug Delivery System4, i.e Mouth 
Dissolving Tablet 
1,2
. 
             The US Food and Drug Administration Centre for Drug Evaluation and Research 
(CDER) defines, in the „Orange Book‟, an ODT as “a solid dosage form containing medicinal 
substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon 
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the tongue”. The significance of these dosage forms is highlighted by the adoption of the 
term, “Orodispersible Tablet”, by the European Pharmacopoeia which describes it as a tablet 
that can be placed in oral cavity where it disperses rapidly before swallowing 
3
. 
1.1. TABLETS: 
              Tablets remain popular as oral dosage form because of the advantages, afforded both 
to the manufacturer [e.g.: simplicity & economy of preparation, stability and convenience in 
packing, shipping, and dispensing] and the patient [e.g.: accuracy of dosage, compactness, 
post ability, blandness of taste and ease of administration
 4
. 
              Although tablets are more frequently discoid in shape, they also may be round, oval, 
oblong, cylindrical or triangular. They may differ greatly in size and weight depending on the 
amount of drug substance present and the intended method of administration. 
Types of Tablets: 
           Tablets are mainly classified into 4 categories according to their route of 
administration. The following are the 4 groups. 
I. Oral tablets for ingestion 
a. Standard compressed tablets 
b. Multiple compressed tablets 
• Compression coated tablet 
• Layered tablet 
• Inlay tablet 
c. Modified Release tablet 
d. Delayed action tablet 
e. Targeted tablet 
• Floating tablet 
• Colon targeting tablet 
f. Chewable tablet 
g. Dispersible tablet 
II. Tablets used in the oral cavity 
a. Lozenges and troches 
b. Sublingual tablet 
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c. Buccal tablet 
d. Dental cones 
e. Mouth dissolved tablet 
III. Tablets administered by other routes 
a. Vaginal tablet 
b. Implants 
IV. Tablets used to prepare solution 
a. Effervescent tablet 
b. Hypodermic tablet 
c. Soluble tablet 
1.2. ORODISPERSIBLE TABLETS:  (ODTs)    
              It is a tablet that disintegrates and dissolves rapidly in the saliva, within a few 
seconds without the need of drinking water or chewing. An orodispersible tablet usually 
dissolves in the oral cavity within 15 s to 3 min. Orodispersible tablets are also known as 
mouth-dissolving tablets, melt-in mouth tablets, Fast dissolving tablets, rapimelts, porous 
tablets, quick dissolving tablet. They have unique property of rapidly disintegrating and/or 
dissolving and releasing the drug as soon as they come in contact with saliva, thus obviating 
the requirement of water during administration
 
and they turn into a soft paste or liquid form 
for easy swallowing, and it is free of risk of choking.  
             Mainly these tablets are prepared by the use of superdisintegrants such as 
crosspovidone, croscarmellosesodium, sodium starch glycolate etc. The super disintegrants 
are added to this formulation to enhance the disintegration of tablet into smaller particles 
which provides rapid onset of action. Most fast dissolving tablets must include substances to 
mask the bitter taste of the active ingredient. This masked active ingredient is then swallowed 
by the patient's saliva along with the soluble and insoluble excipients. It has been concluded 
that faster the dissolution, faster the absorption and onset of action. Some drugs are absorbed 
from the oral cavity, pharynx and oesophagus as the saliva passes down into the stomach and 
avoids the first pass metabolism. Thus the bioavailability of drug is significantly more than 
those observed from conventional tablets dosage form.  
              Super disintegrants play a major role in the disintegration and dissolution of MDT. 
Super disintegrants provide quick disintegration due to combined effect of swelling and water 
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absorption by the formulation which forms a porous structure. The optimum concentration of 
the superdisintegrant can be selected according to critical concentration of disintegrant. 
Below this concentration, the tablet disintegration time is inversely proportional to the 
concentration of the superdisintegrant, whereas if concentration of superdisintegrant is above 
critical concentration, the disintegration time remains almost constant or even increases 
1,2
.  
Advantages of ODTs 
1
: 
• Do not require water to swallow the tablet 
• It can easily administered to geriatric, paediatric and mentally disabled patients. 
• It provides accurate dosing compare to liquids. 
• Dissolution and absorption of drug is fast, thus providing rapid onset of action. 
• Advantageous over liquid medication in terms of administration as well as 
transportation. 
• Suitable for sustained/controlled release actives. 
• It allows high drug loading. 
• Bioavailability of drugs is increased as some drugs are absorbed from mouth, pharynx 
and oesophagus through saliva passing down into the stomach and avoids first pass 
metabolism and thus reduced dose and side effects. 
Limitations 
2
: 
• The tablets generally have insufficient mechanical strength. Hence, careful handling is 
required during manufacturing process. 
• The tablets may leave unpleasant taste and/or grittiness in oral cavity if not 
formulated properly. 
• Drugs with larger doses are difficult to formulate into FDT e.g. rifampin (600 mg), 
ethambutol (1000mg) etc. 
Ideal properties of ODTs 
5
: 
• It requires no water for oral administration. 
• It should have adequate taste-masking properties. 
• It should have pleasant mouth-feel properties, adequate hardness. 
• It should leave little or no residue in mouth after oral administration. 
• It should be compatible with taste masking. 
• It allows high drug loading. 
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• It should exhibit low sensitivity to environmental conditions such as temperature and 
humidity. 
Approaches to achieve the tablets ODTs 
5
: 
• Water must rapidly enter into the tablet matrix to cause rapid disintegration and 
instantaneous dissolution of the tablet. 
• Incorporation of an appropriate disintegrating agent or highly water soluble excipients 
in the tablet formulation. 
            There are some undermentioned mechanisms by which the tablet is broken 
down into the smaller particles and then subsequently result a solution or suspension 
of the drug. The mechanisms are 
• High swellability of disintegrants 
• Chemical reaction 
• Capillary action 
 Technologies used for manufacturing of ODTs 
2,6,7
: 
I. Conventional techniques 
II. Patented techniques 
Conventional techniques: 
1. Freeze drying or lyophilisation: 
     The drug is dissolved or dispersed in an aqueous solution of a carrier. The mixture 
is poured into the wells of the preformed blister packs. The trays holding the blister 
packs are passed through liquid nitrogen freezing tunnel to freeze the drug solution. 
Then the frozen blister packs are placed in refrigerated cabinets to continue the freeze 
drying. Finally the blisters are packaged and shipped. 
Characteristics: Highly porous, have high specific surface area, dissolve rapidly and 
ultimately show improved absorption and bioavailability. 
2. Tablet moulding: 
      Water-soluble ingredients with a hydro-alcoholic solvent is used and is moulded 
into tablets under pressure lower than that used in conventional tablet compression. 
Then the solvent is removed by air drying. 
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Characteristics: Moulded tablets are very less compact than compressed tablet 
porous structure that enhances disintegration/dissolution and finally absorption 
increased. 
3. Direct compression: 
       It is the easiest way to manufacture tablets. Conventional equipment, commonly 
available excipients and a limited number of processing steps are involved in direct 
compression. Also high doses can be accommodated and final weight of tablet can 
easily exceed that of other production methods. 
Characteristics: It is most cost effective tablet manufacturing technique. 
4. Spray drying: 
        By hydrolyzed and non hydrolyzed gelatins as supporting agents, mannitol as 
bulking agent, sodium starch glycolate or crosscarmellose sodium as disintegrating 
agent and an acidic material (e.g. citric acid) and / or alkali material (e.g. Sodium 
bicarbonate) to enhance disintegration /dissolution. 
Characteristics: Prepared tablet disintegrates within 20 seconds when immersed in 
an aqueous medium. 
5. Sublimation: 
        Inert solid ingredients that volatilize rapidly like urea, camphor ammonium 
carbonate, ammonium bicarbonate, hexamethylene tetramine were added to the other 
tablet ingredients and the mixture is compressed into tablets. The volatile materials 
were then removed via sublimation, which generates porous structure. 
Characteristics: Porous structure that enhances dissolution by using volatile material 
or solvent e.g. cyclohexane, benzene etc. 
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                           Figure No: 1 Sublimation process 
 
6. Disintegrant addition method: 
      It involves the addition of superdisintegrants in optimum concentration to the 
formulation to achieve rapid disintegration/dissolution. For e.g. Sodium starch 
glycolate, crystalline cellulose (AvicelPH-102) and low substituted HPEC, 
Crosspovidone and crosscarmellose Na. 
Characteristics: Similar to conventional tablets with higher % of disintegrants, lower 
hardness and higher % of friabilty. 
7. Mass extrusion: 
      This method involves softening the active blend using the solvent mixture of 
water soluble polyethylene glycol, methanol and expulsion of softened mass through 
the extruder or syringe to get a cylindrical shape of the product into even segments 
using heated blade to form tablets. 
Characteristics: The dried product can be used to coat granules of bitter tasting drugs 
and thereby masking their bitter taste. 
8. Cotton candy process: 
      This process is so named as it utilizes a unique spinning mechanism to produce 
floss-like crystalline structure, which mimic cotton candy. It involves the formation of 
matrix of polysaccharides by simultaneous action of flash melting and spinning. This 
candy floss matrix is then milled and blended with active ingredients and excipients 
after re-crystallization and subsequently compressed to FDT. 
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Characteristics: It can accommodate high doses of drug and offers improved 
mechanical strength. 
9. Compaction: 
a) Melt granulation:  
         Prepared by incorporating a hydrophilic waxy binder (super polystate) 
PEG-6-stearate. Super polystate not only acts as binder and increase physical 
resistance of tablet but also helps the disintegration of tablet. The advantage 
of this technique compared to a conventional granulation is that no water or 
organic solvents is needed. Because there is no drying step, the process is 
less time consuming and uses less energy than wet granulation 
Characteristics: It melts in the mouth and solubilizes rapidly leaving no 
residue. 
b) Phase transition process: 
       Prepared by compressing a powder containing two sugar alcohols with 
high and low melting points and subsequent heating at a temperature between 
their melting points. The tablet hardness was increased after heating process 
due to increase of inter particle bond induced by phase transition of lower 
melting point sugar alcohol. 
Characteristics: The compatibility increased and so sufficient hardness 
gained by the formulation. 
10. Nanonization: 
         A recently developed nanomelt technology involves reduction in the particle 
size of drug to nanosize by milling the drug using a proprietary wet-milling technique. 
Nanocrystals of the drug are stabilized against agglomeration by surface adsorption 
on selected stabilizers, which are then incorporated into FDTs. 
Characteristics: It is used for poorly water soluble drugs. It leads to higher 
bioavailability and reduction in dose, cost effective manufacturing process, 
conventional packaging due to exceptional durability and wide range of doses (up to 
200 mg of drug per unit). 
11. Fast dissolving films: 
          A non-aqueous solution is prepared containing water soluble film forming 
polymer (pullulan, cellulose derivatives, polyvinyl pyrrolidone, polyvinyl alcohol or 
sodium alginate, etc.), drug and other taste masking ingredients are used to form a 
film after evaporation of solvent. In case of a bitter drug, resin adsorbate or coated 
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micro particles of the drug can be incorporated into the film. This film, when placed 
in mouth, melts or dissolves rapidly, releasing the drug in solution or suspension 
form. 
Characteristics: The thin films size less than 2X2 inches, dissolution in 5 sec, instant 
drug delivery and flavoured after taste. 
Patented techniques
 7,8
: 
1. Zydis technology: 
         Zydis formulation is a unique freeze dried tablet in which drug is physically 
entrapped or dissolved within the matrix of fast dissolving carrier material. When 
zydis units are put into the mouth, the freeze-dried structure disintegrates 
instantaneously and does not require water to aid swallowing. The zydis matrix is 
composed of many material designed to achieve a number of objectives. To impart 
strength and resilience during handling, polymers such as gelatin, dextran or alginates 
are incorporated. These form a glossy amorphous structure, which imparts strength. 
Zydis products are packed in blister packs to protect the formulation from moisture in 
the environment. 
2. Orosolv technology: 
           In this system active medicament is taste masked. It also contains effervescent 
disintegrating agent. Tablets are made by direct compression technique at low 
compression force in order to minimize oral dissolution time. Conventional blenders 
and tablet machine is used to produce the tablets. The tablets produced are soft and 
friable. 
3. Durasolv technology: 
           The tablets made by this technology consist of drug, filler and a lubricant. 
Tablets are prepared by using conventional punching equipment and have good 
rigidity. These can be packaged into conventional packaging system like blisters. 
durasolv is an appropriate technology for product requiring low amounts of active 
ingredients. 
4. Flashtab technology: 
            Tablet prepared by this system consists of an active ingredient in the form of 
micro crystals. Drug micro granules may be prepared by using the conventional 
techniques like coacervation, micro encapsulation and extrusion spheronisation. All 
the processing utilized conventional tableting technology. 
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5. Wowtab technology: 
            WOW means “Without Water”. In this process, combination of low 
mouldability saccharides and high mouldability saccharides is used to obtain a rapidly 
melting strong tablet. The active ingredient is mixed with a low mouldability 
saccharide (eg. lactose, glucose, and mannitol) and granulated with a high 
mouldability saccharide (eg. Maltose, oligosaccharides) and compressed into tablet. 
6.  Oroquick technology: 
          The OraQuick fast-dissolving/disintegrating tablet formulation utilizes a 
patented taste masking technology. It is microsphere technology, known as 
MicroMask, has superior mouthfeel over taste-masking alternatives. The taste 
masking process does not utilize solvents of any kind, and therefore leads to faster 
and more efficient production. Also, lower heat of production than alternative fast-
dissolving/disinte-grating technologies makes OraQuick appropriate for heat-sensitive 
drugs.  The matrix surrounds and protects the drug powder in microencapsulated 
particles is more pliable, meaning tablets can be compressed to achieve significant 
mechanical strength without disrupting taste masking. OraQuick claims quick 
dissolution in a matter of seconds, with good taste-masking. There are no products 
using the OraQuick technology currently on the market, but KV Pharmaceutical has 
products in development such as analgesics, scheduled drugs, cough and cold, 
psychotropics, and anti-infectives 
7. Flash dose technology: 
             Nurofen meltlet, a new form of ibuprofen as melt in mouth tablets prepared 
using flash dose technology is the first commercial product launched by biovail 
corporation. Flash dose tablets consist of self-binding shear form matrix termed as 
“floss”. Shear form matrices are prepared by flash heat processing. 
8. Ziplet technology: 
          AdvaTab is distinct from other ODT technologies as it can be combined with 
Eurand‟s complimentary particle technologies like its world leading Microcaps® 
taste-masking technology and its Diffucaps® , controlled release technology. The 
pairing of AdvaTab with Microcaps creates products that offer the dual advantage of a 
patient preferred dosage form, together with a superior taste and smooth mouth feel. 
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           Table No: 1  Patented technologies and their brand products
 2 
S.No Technique            Novelty  Patent owner Drugs used (brand name) 
1. Zydis First to market, Freeze 
dried 
R.P.Scherer 
Inc. 
Loratidine (Claritin Reditab 
and Dimetapp Quick 
Dissolve) 
2. Orosolv Unique taste-masking, 
lightly compressed 
Cima Labs Inc. Paracetamol (Tempra 
Quicklets),Zolmitriptan 
(Zolmig Repimelt) 
3. Durasolv Compressed dosage form, 
Proprietary taste masking. 
Cima Labs Inc. Hyoscyamine Sulfate 
(NuLev)Zolmitriptan 
(Zolmig ZMT) 
4. Flashtab Compressed dosage form 
containing drug as micro- 
crystals 
Ethypharm Ibuprofen (Nurofen 
Flashtab) 
5. Wowtab Combination of low -
mouldability and high -
mouldabiity saccharides. 
Smoothmelt action gives 
superior mouth feel. 
Yamanouchi 
Pharma 
Technologies, 
Inc. 
Famotidine (Gaster D) 
6. Oraquick Uses patented taste 
masking technology 
KV Pharm. Co., 
Inc. 
Hyoscyamine Sulfate ODT 
7. Flashdose Unique spinning 
mechanism to produce a 
floss-like crystalline 
structure, much like cotton 
candy. 
Fuisz 
Technology 
Ltd. 
Tramadol HCl (Relivia 
Flash dose) 
8. Ziplet/ 
advatab 
Incorporation of 
waterinsoluble 
inorganic 
excipients for excellent 
physical performance 
Eurand 
International 
AdvaTab cetrizine, 
AdvaTab Paracetamol 
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               Table No: 2    Important patented technologies for preparation of ODTs 
2 
S.No Technique Process involved          Advantages        Disadvantages 
1. Zydis Lyophilization Quick dissolution, Self-
preserving and increased 
bioavailability. 
Expensive process, poor 
stability at higher 
temperature and 
humidity. 
2. Orosolv Compressed 
tablets 
Taste-masking is twofold, 
quick dissolution. 
Low mechanical strength. 
3. Durasolv Molding Higher mechanical 
strength than Orasolv, 
Good rigidity. 
Inappropriate with larger 
dose. 
4. Flashtab Lyophilization Only conventional 
tableting technology 
 
                  - 
5. Wowtab Compressed 
molded tablets 
Adequate dissolution rate 
and hardness. 
No significant change in 
bioavailability. 
6. Oraquick Micromask taste 
masking 
Faster and efficient 
production, appropriate for 
heat-sensitive drugs. 
 
                  - 
 
7. Flashdose Cotton-candy 
process 
High surface area for 
dissolution 
High temperature 
required to melt the 
matrix can limit the use 
of heat-sensitive drugs, 
sensitive to moisture and 
humidity. 
8. Ziplet/ 
advatab 
Molding Good mechanical strength, 
satisfactory properties can 
be obtained at high dose 
(450 mg) and high weight 
(850 mg). 
As soluble component 
dissolves, rate of water 
diffusion in to tablet is 
decreased because of 
formation of viscous 
concentrated solution 
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1.3. SUPERDISINTEGRANTS (SDs) 
1
: 
               Use of superdisintegrants is basic approach in development of ODTs and plays 
important role like discussed above. The following are some mechanisms through which the 
SDs shows their action. 
Mechanisms of SDs: 
a. By capillary action (wicking):  
          Disintegration by capillary action is always the first step. When we put the 
tablet into suitable aqueous medium, the medium penetrates into the tablet and 
replaces the air adsorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. Water uptake by tablet depends upon 
hydrophilicity of the drug /excipient and on tableting conditions. 
b. By swelling: 
           The most widely accepted general mechanism of action for tablet 
disintegration is swelling. Tablets with high porosity show poor disintegration due to 
lack of adequate swelling force. On the other hand, sufficient swelling force is exerted 
in the tablet with low porosity. It is worthwhile to note that if the packing fraction is 
very high, fluid is unable to penetrate in the tablet and disintegration is again slows 
down. 
                 Figure No: 2 Disintegration of tablet by wicking and swelling 
                           
                                  WICKING                                    SWELLING 
                               Water is pulled by disintegrant             Particles swell and break up 
                                   and reduced the physical                      the matrix form within 
                   bonding force between particles 
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c. Because of heat of wetting (air expansion): 
          When disintegrants with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet. This 
is limited to only a few types of disintegrants and cannot describe the action of most 
modern disintegrating agents. 
d. Due to release of gases: 
         Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid and generates pressure 
within the tablet due to which the tablet disintegrants. This effervescent mixture is 
used when pharmacist needs to formulate fast disintegrating tablet. As these 
disintegrants are highly sensitive to small changes in humidity level and temperature, 
strict control of environment is required during manufacturing of the tablets. The 
effervescent blend is either added immediately prior to compression or can be added 
in to two separate fraction of formulation. 
e. By enzymatic reaction: 
         Here, enzymes present in the body act as disintegrants. These enzymes destroy 
the binding action of binder and helps in disintegration. But actually the disintegration 
occurs by swelling. 
f. Due to disintegrating particle/particle repulsive forces: 
         Guyot‐Hermann has proposed a particle repulsion theory based on the 
observation that nonswelling particle also cause disintegration of tablets. The electric 
repulsive forces between particles are the mechanism of disintegration and water is 
required for it. Researchers found that repulsion is secondary to wicking. This is the 
swelling of tablet made with non-swellable disintegrants. 
g. Due to deformation: 
       Hess had proved that during tablet compression, disintegranted particles get 
deformed and these deformed particles get into their normal structure when they come 
in contact with aqueous media or water. Occasionally, the swelling capacity of starch 
was improved when granules were extensively deformed during compression. 
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                             Figure No: 3 Disintegration by deformation and repulsion 
                                        
                                          DEFORMATION                        REPULSION 
                         Particles swell to precompression         Water is drawn into poresand 
                              size and break up matrix                  particles repel each other because of 
                                                                                                   resulting electrical force. 
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              Table No: 3  List of some superdisintegrants used in ODTs preparation 
2 
Superdisintegrant Nature Properties Mechanism 
Crosspovidone     
 
Crosslinked homo 
polymer of N-vinyl-2-
pyrrolidone 
Particle size - 100 μm, insoluble 
in water, gives smoother mouth 
feel 
Both swelling 
and wicking 
Cross carmellose 
sodium  
Cross-linked form of 
sodium CMC  
Particle size 200 mesh, insoluble 
in water  
Swelling  
 
Sodium starch 
glycolate  
 
Crosslinked low 
substituted 
carboxymethyl ether 
of poly-glucopyranose  
 
Particle size 140 mesh, insoluble 
in organic solvents, disperses in 
cold water and settles in the 
form of a highly saturated layer  
Water uptake 
followed by 
rapid and 
enormous 
swelling  
Acrylic acid 
derivatives 43 
(Yang et al. 2004)  
Poly(acrylic acid) 
super porous hydrogel  
Particle size 106 μm, DT- 15 + 2 
S  
 
Wicking action  
 
Effervescent 
mixture  
 
Citric acid, tartaric 
acid, sodium 
bicarbonate  
Crystalline nature  
 
Effervescence  
 
Sodium alginate  Sodium salt of alginic 
acid  
Slowly soluble in water, 
hygroscopic in nature  
Swelling  
 
NS-300 43  
(Ozeki et al. 2003) 
Carboxy methyl 
cellulose  
Particle size 106 μm,  
DT - 20 S  
Wicking type  
ECG-505 43 
 (Ozeki et al. 2003)  
Calcium salt of CMC  Particle size 106 μm, DT - 80S  Swelling type  
 
L-HPC 43  
(Ozeki et al. 2003)  
Low hydroxy propyl 
cellulose  
Particle size 106 μm, DT-90S  Both swelling 
and wicking  
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1.4. TASTE MASKING METHODS FOR ODTs 
8
: 
          The drugs are mostly bitter in nature. Taste masking is needed to hide the bitter taste in 
ODTs formulations which can be achieved by using combination of right flavour and right 
sweeteners. Methods used in taste masking are given as follows:  
a. Incorporation of Sweeteners and Flavours:  
                  Different flavours are used in ODT formulations to mask the bitter taste and give       
pleasant mouth feel. Most commonly used flavours are mint, orange, strawberry, pineapple, 
peppermint flavours. Mannitol and aspartame are most widely used excipients in formulating 
ODTs.  
b. Adjustment of pH values:  
                  Many drugs are less soluble at pH different from the pH of the mouth, which are 
around 5.9. Drugs can be insufficiently solubilized to be available to taste if the equilibrium 
concentration is below the taste threshold.  
c. Effervescent Technique:  
                  The bitter taste of the drugs can be masked as effervescent tablet rapidly 
disintegrates and carbon dioxide is produced by contact with saliva or aqueous fluid.  
d. Spray Drying Technique : 
                  Simple wet granulation method or roller compaction of other excipients. Spray 
drying can also employed to shroud the drug.  
e. Coating of Drug Particles with Inert Agents:  
                  Coating is an extremely useful technique for number of applications in the 
pharmaceutical field. By using the right type of coating material it is possible to completely 
mask the taste of a bitter drug, while at the same time, not adversely affecting the intended 
drug release profile. Any nontoxic polymer that is insoluble at pH 7.4 and soluble at acidic 
pH would be an acceptable alternative for taste masking.  
f. Taste Masking by Formation of Inclusion Complexes:  
                  The complexing agent is capable of masking the bitter taste of the drug by 
decreasing the amount of drug particles exposed to taste buds thereby reducing the perception 
of bitter taste. Mainly involved forces in inclusion complexes are Vander Waals forces. Most 
widely used complexing agent is Beta-cyclodextrin for inclusion type complexes. It is sweet, 
nontoxic, cyclic oligosaccharide obtained from starch. Cyclodextrin help to solubilize many 
drugs.  
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g. Solid Dispersion System:  
                     Solid dispersion is also called as co precipitates for those preparations obtained 
by solvent method such as co precipitates of sulphathiazole and povidone. Solid dispersions 
using insoluble matrices or bland matrices may be used to mask the bitter taste of drugs. Also 
using them as absorbents on various carriers may increase the stability of certain drugs. 
h. Microencapsulation:  
                     Microencapsulation as a process has been defined by Bakan as a means of 
applying relatively thin coating to small particles of solid, droplets of liquid and dispersion54. 
This process can be used for masking of bitter tasting drugs microencapsulating drug 
particles with various coating agents.  
i. Mass Extrusion Method (Dispersion coating):  
                    This technology involves softening the active blend using the solvent mixture of 
water-soluble polyethylene glycol, using methanol and expulsion of softened mass through 
the extruder or syringe to get a cylinder of the product into even segments using heated blade 
to form tablets.  
j. Ion Exchange Resin:  
                  When the drug resinates comes into contact with the gastrointestinal fluids, such 
as the acid of the stomach. The drug is released from resinate directly into solution and then 
absorbed in the usual way. The resin passes through the GI tract without being absorbed. 
Examples of drugs where this technique has been successfully demonstrated include 
ranitidine, risperidone and paroxetine.  
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LITERATURE REVIEW 
Prashant Khemariya et al 
13
: They prepared mouth dissolving tablets of meloxicam 
which is a newer selective COX-1 inhibitor. They prepared the tablets by wet granulation 
procedure and evaluated for % friability, wetting time and disintegration time. They 
found that sublimation of camphor from tablets resulted in better tablets as compared to 
the tablets prepared from granules that were exposing to vacuum. 
Metker Vishal et al
 14
: They have developed orodispersible tablets of lornoxicam using 
kyronT-314 (polacrillin potassium) as a novel superdisintegrant. They are prepared by 
wet granulation method using Kyron T-314 and menthol as sublimating agent and 
menthol as sublimating agent for rapid absorption, improved bioavailability, effective 
therapy and patient compliance. 
Prabhakar Reddy Veerareddy et al 
15
:  They have prepared and evaluated the fast 
dissolving tablets of ketorolac tromethamine using a combined approach of subliming 
agent and superdisintegrant. FDTs were prepared by direct compression technique. The 
prepared tablets were dried under vacuum for camphor sublimation that results porous 
structure in the tablet which results faster disintegration and drug release. They evaluated 
the tablets for various tests. The porous structure of the tablet was observed under 
scanning electron microscopy (SEM). Their results showed low weight variation, good 
hardness, acceptable friability. 
Dr. Srinivasa Rao Y et al 
16
: Designed FDTs of taste-masked ondansetron HCl using 
eudragit E 100 as a taste masking agent. They used mass extrusion method to prepare 
taste-masked granules. The drug polymer complexes were tested for drug content,in vitro 
taste evaluation in SSF of pH 6.2 and drug excipient interaction. They considered a 
complex as taste masked which did not release drug in SSF and selected the same for the 
formulation of FDTs. Indion-414 was used as the superdisintegrant. 
Uddhav Bagul et al 
17
: They developed fast melt tablets of levocetirizine dihydrochloride 
by using sublimation technique which were prepared by direct compression method using 
different concentrations of spray dried mannitol (Perlitol SD200), menthol and camphor. 
The sublimation technique is used to increase the porosity of the tablets in which menthol 
and camphor were used as subliming agents which in turn forms the porous structure on 
the surface of tablets after sublimation. The in vitro drug release study revealed that 
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menthol and camphor (1:1) at a concentration of 20 % (Batch – LMD-6)of the total 
weight of the tablet offer fast release of Levocetirizine dihydrochloride within 5 minutes. 
These tablets also dissolved within 15-20 seconds in saliva with pleasant taste and smooth 
mouth feel. 
Basawaraj S.Patil et al
 18
:  They prepared fast dissolving tablets of Granisetron 
hydrochloride by vacuum drying technique using camphor as subliming agent together 
with croscarmellose sodium, crospovidone, sodium starch glycolate and plantago ovate as 
superdisintegrants. They have concluded that fast dissolving tablets with improved 
granisetron hydrochloride dissolution could be prepared by sublimation of tablets 
containing suitable subliming agent. 
Nagendra Kumar D et al
 19
:  They have formulated fexofenadine hydrochloride fast 
dissolving tablets by sublimation method. In this method, camphor was used as the 
subliming agent (upto 30% w/w), crospovidone and croscarmellose sodium (2-8% w/w) 
were used as superdisintegrants. Estimation of fexofenadine hydrochloride in the 
prepared tablet formulations was carried out by extracting the drug with methanol and 
measuring the absorbance at 259 nm. Based on in vitro dispersion time (approximately 5-
14 sec), two promising formulations (one from each super-disintegrant) were tested for 
in-vitro drug release pattern in pH 6.8 phosphate buffer. They found that among the two 
promising formulations, the formulation (SCP3) containing 8% w/w of crospovidone and 
30% w/w camphor as the subliming agent emerged as the overall best formulation 
(t50%4.3 min) based on drug release characteristics in pH 6.8 phosphate buffer compared 
to commercial conventional tablet formulation (t50%15 min). 
D.G.Umalkar et al
 20
: They designed mouth dissolving tablet of zopicolon using 
combination of super-disintegrants i.e.Ac-di-sol (croscarmellose sodium), polyplasdone 
XL-10, microcrystalline cellulose pH 102 along with directly compressible dextrose to 
improve mouth feel. The formulation prepared by direct compression method using Ac-
di-sol (croscarmellose sodium) 50mg, polyplasdone XL- 10 -25mg, microcrystalline 
cellulose pH 102- 25mg was found to be better formulation T80% = 5 min based on in- 
vitro drug release characteristics. 
S Furtado et al 
21
: Developed and characterized the orodispersible tablets of famotidine 
containing camphor as a subliming agent. Sodium starch glycolate and crosscarmellose 
sodium were used as superdisintegrants. They evaluated the prepared tablets for various 
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tests. They observed that the tablets containing subliming agent had a good dissolution 
profile. 
Patel Bipin et al
 22
: Developed mouth dissolving tablets of cinnarazine which is H1-
receptor antagonist and widely used in the treatment of motion sickness, vomiting and 
vertigo. Mouth dissolving tablets of cinnarizine were prepared by effervescent, 
superdisintegrant addition and sublimation methods among which superdisintegrant 
addition method showed lowest disintegration time; hence it was selected for further 
studies. Further nine batches (B1-B9) were prepared by using crospovidone, 
croscarmellose sodium and L-HPC in different concentrations such as 5%, 7.5% and 
10%. Formulation with 10% L-HPC showed less disintegration time (25.3 seconds) and 
less wetting time (29.1 seconds) and in-vitro dissolution studies showed total drug release 
at the end of 6 minutes. 
Vijay Tiwari et al
 23
: They have researched to study fast dissolving tablets of celecoxib 
using soliddispersion of celecoxib and sorbitol by holt melt extrusion process, and 
superdisintegrants (sodium starch glycolate), binder (polyvinylpyrrolidone), sweetner 
(saccharine sodium), flavour (menthol). They have prepared six different formulations of 
solid dispersion and the batch having the best drug release profile was used for the 
preparation of nine batches of fast dissolving tablets by direct compression method. It has 
shown that the batch of solid dispersion containing maximum concentration of sorbitol 
polymer is showing best drug release and in fast dissolving tablets the batch containing 
maximum concentration of superdisintegrant is showing the best drug release (99.74% in 
30 min). They concluded the bioavailability of celecoxib is increased by fast dissolving 
dosage form. 
Ashwini R.Madgulkar et al
 24
: Developed novel taste masked mouth-dissolving tablets 
of tramadol that overcomes principle drawback of such formulation which is inadequate 
mechanical strength. The crucial aspect in the formulation of mouth-dissolving tablets is 
to mask the bitter taste and to minimize the disintegration time while maintaining a good 
mechanical strength of the tablet. They masked the bitter taste of tramadol HCl by 
forming a complex with an ion exchange resin Tulsion335. The novel combination of a 
superdisintegrant and a binder that melts near the body temperature was used to formulate 
mechanically strong tablets that showed fast disintegration. A 32 full factorial design and 
statistical models were applied to optimize the effect of two factors, i.e., superdisintegrant 
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(crospovidone) and a mouth-melting binder (Gelucire 39/01). It was observed that the 
responses, i.e., disintegration time and percent friability were affected by both the factors. 
The statistical models were validated and can be successfully used to prepare optimized 
taste masked mouth-dissolving tablets of Tramadol HCl with adequate mechanical 
strength and rapid disintegration. 
Sachin B.Mahamuni et al
 25
: Formulated fast dissolving tablets which can rapidly 
disintegrate in the saliva using taste-masked granules of drugs with a bitter taste, 
promethazine HCl (PM HCl) which were prepared using gastro erodible aminoalkyl 
methacrylate copolymers (Eudragit E-100) by extrusion method. Fast dissolving tablets 
were prepared by direct compression method using taste-masked granules and a mixture 
of excipients containing optimized level of microcrystalline cellulose (Avicel PH-101) 
and starch. The effect of various superdisintegrants crospovidone (Polyplasdone XL), 
sodium starch glycolate (Primogel), croscarmellose sodium (Ac-Di-Sol)] was also 
studied. The dissolution rate was significantly improved with FDT formulated with taste 
masked granules of PM HCl as compared with unmasked granules. This could be 
accounted to the effect of Eudragit E-100 on the dissolution profile of PM HCl and also 
aiding in masking the bitter taste.  
Vineet Bharadwaj et al
 26
: They prepared fast dissolving tablets of amlodipine besylate 
by sublimation method using camphor as sublimating agent. The tablets are prepared by 
direct compression method. They used different concentrations (2%, 4%, 6%) of 
superdisintegrants such as Ac-Di-Sol, sodium starch glycolate, kollidon-CL were used 
respectively. Amongst all formulations, formulation prepared by 6% Ac-Di-Sol showed 
least disintegrating time of 11sec and faster dissolution. Formulation F9 was then studied 
for accelerated stability studies as per ICH guidelines for 60 days that shows no 
remarkable change in the formulation. 
Anupama Kalia et al
 27
: Mouth dissolving tablets of oxcarbazepine are produced by 
direct compression method contain crospovidone as a superdisintegrant and aspartame as 
a sweetener. Solid dispersions of oxcarbazepine with polyvinylpyrrolidone K-30 and 
polyethylene glycol 6000 in different weight ratios were prepared with a view to increase 
its water solubility. Oxcarbazepine solid dispersions with polyvinylpyrrolidone K-30 in 
1:2 ratios of drug: carrier showed maximum drug release and hence, compressed along 
with other excipients into mouth dissolving tablet. The results compared for both the 
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technologies showed that the oxcarbazepine tablets prepared using solid dispersion 
technology was found to have good technological properties and satisfying and 
reproducible drug dissolution profiles.  
D.Nagendrakumar et al
 28
: They formulated fast dissolving tablets of granisetron HCl 
using novel co-processed superdisintegrants consisting of crospovidone and 
crosscarmellose sodium in the different ratios (1:1, 1:2 & 1:3). Based on in vitro 
dispersion time (approximately 20 sec), promising formulation CP1 was tested for in vitro 
drug release pattern in pH 6.8 Phosphate buffer and short-term stability (at 400C/75% RH 
for 3 months), drug excipients interaction (IR spectroscopy) were studied. Among the 
designed formulations, the formulation (CP1) containing 4% w/w of coprocessed 
superdisintegrant (1:1 mixture of crospovidone and crosscarmellose sodium ) emerged as 
the overall best formulation (t50% 3.0 min) based on drug release characteristics in pH 
6.8 phosphate buffer compared to commercial conventional tablet formulation (t50% >15 
min). 
Shailendra Kumar Singh et al
 29
: Prepared fast disintegrating combination tablets of 
omeprazole and domperidone using Mannitol as diluent and sodium saccharin as 
sweetening agent along with three different levels of disintegrant. They used Kollidon 
CL, Ac-Di-Sol and SSG as superdisintegrants. The tablets were prepared by direct 
compression method and evaluated for various tests. Drug content was estimated by using 
HPLC method and also assay of sample was compared with standard drugs. From the 
results obtained they concluded that the tablet formulation prepared with 4.76% Ac-Di-
Sol showed disintegration time of 15 seconds in vitro and also satisfied the other tests. 
Dr. C.S.R. Lakshmi et al 
30
: They compared the effect of subliming agents on the oral 
dispersible properties of cinnarazine tablets. The fundamental principle used in the 
development of oral dispersible tablets by sublimation technique is to maximize pore 
structure of the tablets the compressed tablets prepared by using water soluble materials 
like mannitol, does not rapidly disperse in water since it is difficult for water to penetrate 
into the tablets due to their low porosity. To increase the porosity of the tablets which are 
prepared by direct compression using Mannitol, subliming agents such as camphor, 
menthol, ammonium bicarbonate or thymol are to be used. A high porosity was achieved 
due to the formation of many pores where camphor, menthol, ammonium bicarbonate and 
thymol particles previously existed in the compressed Mannitol tablets prior to 
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sublimation of these subliming materials. These compressed tablets which have high 
porosity rapidly dissolved within 25 seconds. 
Suhas M. Kakade et al
 31
: Designed mouth dissolving tablets of losartan potassium to 
improve its dissolution rate and bioavailability which has low bioavailability due to first 
pass metabolism. Tablets prepared by direct compression and using super disintegrants 
like polyplasdone XL 10, croscarmellose sodium and explotab in different concentrations. 
Among all, the formulation containing 5%w/w superdisintegrant polyplasdone XL 10 was 
considered to be best formulation, which release up to 99.26% in 12 min. 
Hindustan Abdul Ahad et al
 32
: A novel attempt has been made to develop mouth 
dissolving tablets of nimesulide by including clove oil as flavouring and local anaesthetic 
agent on taste buds. The tablets were prepared by direct compression method. The 
formulated tablets were evaluated for Pre-formulation and post formulation parameters 
and they were found to be satisfactory. The formulated mouth dissolving tablets possess 
good drug releasing property, good mouth feel and improved drug availability with better 
patient compliance. 
Siva Prasad Reddy et al 
33
: A novel attempt has been made to design mouth dissolving 
tablets of clozapine by inclusion of clove oil as a flavouring agent which also has local 
anaesthetic action on taste buds of tongue. Additionally stevia leaf powder was included 
as sweetener which has 400 times sweeter than sucrose. The tablets were prepared by 
direct compression technique and evaluated for pre compression and post compression 
properties which were found to be satisfactory. 
Srinivas Pannala et al 
36
: Prepared nizatidine immediate release tablets to deliver a 
programmed dose of drug intended for excessively secreted gastric acid and for 
promoting healing of duodenal ulcers thereby spontaneously delivering the drug when 
exposed into GIT for producing an anti-ulcer effect. These immediate release drug 
containing core tablets of nizatidine were prepared by wet granulation method. The 
prepared tablets were evaluated for various tests and stability was tested as per ICH 
guidelines. 
Sachin Sharma et al
 37
: Formulated mouth dissolving tablets of the ranitidine HCl to 
improve its bioavailability as it undergoes first pass metabolism and shows only 50% 
bioavailability. They prepared the tablets using sublimation method using ammonium 
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bicarbonate as subliming agent and evaluated for various tests. They also prepared other 
tablets using superdisintegrants sodium starch glycolate and cross carmellose sodium. 
Finally they reported that the tablets prepared by superdisintegrant addition have better 
disintegrating properties and release. 
P.V.Swamy et al
 40
: Designed orodispersible tablets of pheniramine by effervescent 
method with a view to enhance patient compliance. In the effervescent method, mixture 
of sodium bicarbonate and tartaric acid (each of 12% w/w concentration) were used along 
with super disintegrants, i.e., pregelatinized starch, sodium starch glycolate, 
croscarmellose sodium and crospovidone. Based on in vitro dispersion time 
(approximately 60 s), three formulations were tested for in vitro drug release pattern (in 
pH 6.8 phosphate buffer), short-term stability (at 40±2°/75±5% RH for 3 months) and 
drug-excipient interaction (IR spectroscopy). Among three promising formulations, 
formulation ECP4 containing 4% w/w crospovidone and mixture of sodium bicarbonate 
and tartaric acid (each of 12% w/w) emerged as the overall best formulation (t70% = 1.65 
min) based on the in vitro drug release characteristics compared to commercial 
conventional tablet formulation.                
Jyothi Singh et al 
42
: They formulated orodispersible tablets which can rapidly 
disintegrate in saliva using taste-masked granules of drug, Tizanidine HCl. They prepared 
the taste-masked granules using gastro-erodible aminoalkyl methacrylate copolymer 
(Eudragit E-100) in different ratios by extrusion method. Drug-polymer complexes were 
tested for drug content and in vitro drug release in simulated salivary fluid (SSF) of pH 
6.8. They selected the complex that did not release drug in SSF which has been 
considered as taste-masked for formulation of ODTs. They also studied the effect of 
various super disintegrants such as chitosan, Croscarmellose sodium and sodium starch 
glycolate in formulation of ODTs. 
Sunil H. Makwana et al 
43
: They masked the intensely bitter taste of ondansetron HCl 
with indion-204 in different ratios by the solvent evaporation and formulated a 
orodispersible of the taste masked drug. Drug-resin complex were optimized by 
considering parameters such as optimization of resin concentration, optimization of 
swelling time, optimization of stirring time, optimization of pH and optimization of 
temperature on maximum drug loading and they observed the effect of variables on 
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maximum amount of the drug loading. Resinate was evaluated for taste masking, 
characterized by X-ray diffraction and IR spectrometer. 
Seong Hoon Jeong et al 
47
: FDTs are prepared by several different methods including 
crystalline transition, phase transition, sublimation, spray drying, and direct compression. 
Of these approaches, a conventional tablet compression method is used most widely 
because of its low cost and ease of manufacturing. Research on FDTs prepared by the 
compression method has focused on decreasing the dissolution time of the tablets in the 
mouth, while maintaining sufficiently high mechanical strength to withstand handling 
during manufacturing, packaging and transportation. The key to developing a successful 
FDT formulation by the compression method is to select the right excipients and the right 
processing techniques. 
D.R.Brahma Reddy et al 
49
: Over the past three decades, Rapimelts have gained 
considerable attention as a preferred alternative to conventional tablets and capsules due 
to their better patient compliance. Orally disintegrating tablets offer an advantage for 
populations who have difficulty in swallowing. Prescription Rapimelts products initially 
were developed to overcome the difficulty in swallowing conventional tablets with water 
among pediatric, geriatric and psychiatric patients with dysphagia. Today, Rapimelts are 
widely available as the over-the-counter drugs for the treatment of allergies and cold and 
flu. Technologies used for manufacturing of orally disintegrating tablets are either 
conventional technologies or patented technologies. 
Sunil Kumar Jain et al 
53
: Developed mouth dissolving tablets of ibuprofen by using 
optimized solid dispersion of the same along with superdisintegrants, which was prepared 
by using different concentrations of drug and PEG 4000. The prepared solid dispersion 
formulations were characterized by FT-IR, DSC, XRD and in vitro drug release. From IR 
and XRD studies, it may be concluded that there is change in crystalline form of drug into 
amorphous during formation of solid dispersion. From DSC studies, it was predicted that 
drug was completely dissolved in the carrier. 
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RESEARCH ENVISASED 
OBJECTIVE OF THE WORK: 
            Recent advances in technology have presented viable dosage alternative for patients 
who may have difficulty in swallowing tablets or capsules. An orodispersible tablet is one 
such approach. Orodispersible tablets are an innovative technology, which disperse rapidly, 
usually in a matter of seconds, without the need for water, providing optimal convenience to 
the patient. Orodispersible tablets offer many advantages like rapid onset of action, useful for 
pediatric, geriatric and psychiatric patients, good chemical stability, as well as improved 
taste.   
              Most orodispersible tablets must include substances to mask the bitter taste of the 
active ingredients. This masked ingredient is then swallowed by patient along with the 
soluble and insoluble excipients.  It has been concluded that faster the dissolution, faster the 
absorption and onset of action .The time of disintegration of orodispersible tablets is 
generally considered to be less than one minute. 
              Orodispersible tablet of Nizatidine was developed in present study to get rapid onset 
of action, to increase bioavailability and to increase patient compliance. Nizatidine is very 
bitter in taste and if it is incorporated directly in to an orodispersible tablet, the formulation of 
the dosage will definitely get futile and reduce levels of patient compliance, thereby lowering 
therapeutic efficacy. So an unpleasant tasting active substance needs to be masked for only a 
short period of time in the mouth and the throat which requires effective coating for good 
results. The methacrylate copolymer, Eudragit E100 is very suitable for this purpose which 
shows excellent taste masking properties even at low film thickness. 
Thus the present study has been made to mask the taste of Nizatidine using Eudragit 
E100 and to formulate orodispersible tablet with good mouth feel so as to prepare a ‘’patient 
friendly dosage forms’’. 
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PLAN OF WORK 
      The present work was carried out to mask the taste and prepare orodispersible tablets of 
Nizatidine using different superdisintegrants. The following experimental protocol allows a 
systemic approach to the study.  
 Preformulation study 
 Preparation of standard curves 
 Compatibility study of Nizatidine with excipients 
 Masking the bitter taste 
 Preparation of Drug Polymer complex 
 Determination of drug content 
 In Vitro taste evaluation 
 Formulation of  Orodispersible tablets by using different superdisintegrants 
 Evaluation of   precompression properties of powder blend 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner ratio 
 Angle of repose 
 Preparation of Orodispersible tablets 
 Evaluation parameters of the Orodispersible tablets 
 Weight variation 
 Thickness 
 Hardness 
 Friability 
 Wetting time 
 In Vitro dispersion time 
 Disintegration time 
 Taste 
 In Vitro dissolution  
 Assay  
 Content uniformity 
 Determination of stability of orodispersible tablets as per ICH guide lines 
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DRUG PROFILE 
NIZATIDINE: 
Niztidine is an anti-histaminic drug.  
Chemical structure:    
                                  Fig No.4. Structure of Nizatidine 
               
IUPAC name          :   N-(2-[(2-[(dimethyl amino) methyl ] thiazol-4-yl) methyl thio ] ethyl )  
                                   –N-methyl-2-nitroethene-1,1-diamine. 
Molecular formula :  C12H21N5O2S2 
Molecular weight   :  331.46 g/mol 
Category                 :   Anti-ulcer agent, Histamine H2 antagonist  
PROPERTIES 
Description              :   Off white to brown crystalline powder  
Solubility                 :   Freely soluble in water, methanol 
Melting point          :   203
0
C 
Half life                    :  1-2 hrs 
Bioavailability         :  70% 
Plasma protein binding  : 35%, mainly to α1-acid glycoprotein 
Volume of distribution   : 0.8 to 1.5 L/kg 
Onset of action          : 30 min 
Peak                          : 0.5 – 3 hrs 
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Metabolism              :  Metabolized in the liver to active N-desmethylnizatidine (60% as  
                                      active as Nizatidine in blocking acid secretion), and inactive   
                                      Nizatidine N-oxide and nizatidine sulfoxide. 
Excretion                  : Excreted principally in urine. 
MECHANISM OF ACTION: 
        Reversibly and competitively blocks histamine at H 2 receptors, particularly those in 
gastric parietal cells, antagonising the usual stimulatory effect of endogenous histamine on 
gastric acid production. 
DOSAGE AND ADMINISTRATION: 
1. Duodenal Ulcer: 300 mg at bedtime or 150 mg twice daily for up to 8 weeks. 
2. Benign Gastric Ulcer: 300 mg at bedtime or 150 mg twice daily. 
3. Gastroesophageal Reflux Disease: 150 mg daily (Adults), 150 mg twice daily up to  
                                                           8 weeks (Children 12 yr of age and older). 
4. Acid Reduction/ Dyspepsia: 75 mg once or twice daily. 
INDICATIONS: 
        Treatment and maintenance of duodenal ulcer, gastroesophageal reflux disease (GERD) 
(including erosive or ulcerative disease), and benign gastric ulcer; prevention of heartburn, 
acid indigestion, and sour stomach brought on by consuming food and beverages 
CONTRAINDICATIONS: 
        Hypersensitivity to H 2 antagonists, cirrhosis of the liver, impaired renal or hepatic 
function. 
ADVERSE REACTIONS:  
            Common adverse effects are head ache and dizziness. 
Cardiovascular: Ventricular tachycardia. 
CNS                  : Headache, dizziness, abnormal dreams, nervousness. 
Dermatologic   : Pruritus. 
GI                     : Abdominal pain, diarrhoea, flatulence, nausea, vomiting.  
Hepatic            : Elevated liver enzymes.       
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EUDRAGIT E100 
56
: 
       Eudragit E100 is a cationic copolymer based on dimethylaminomethyl methacrylate, 
butyl methacrylate and methyl methacrylate. 
Nonproprietary names: 
           PhEur    : Basic Butylated Methacrylate Copolymer  
           USPNF : Amino Methacrylate Copolymer-NF  
           JPE        : Aminoalkyl Methacrylate Copolymer E  
Physical description:  
       It consists of colourless to yellow tinged granules with a characterstic amine like odour. 
Chemical structure: 
                                    Fig No.5.  Structure of Eudragit E100 
                                  
IUPAC name : Poly(butyl methacrylate-co-(2- demethylaminoeethyl) methacrylate-co-
methyl methacrylate) 1:2:1  
INCI name : Acrylates/ Dimethylaminoethyl Methacrylate Copolymer 
Molecular weight: approx. 47,000 g/ mol  
Characteristics: 
       Low viscosity, high pigment binding capacity, good adhesion and low polymer weight 
gain. 
 
Dissolution:   
 Soluble in gastric fluid up to pH 5.0 
 Swellable and permeable above pH 5. 
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Alkali value : 180 mg KOH/ g polymer 
 
Glass transition temp( Tg) : ~ 48°C  
 
Pharmaceutical applications: 
              Eudragit E polymers help you to seal sensitive actives and increase patient 
compliance by masking tastes and odours. Even thin layers of Eudragit provide the desired 
effect, making it an extremely economical application. Pharma polymers offer various 
cationic Eudragit E grades for protective coatings. 
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SODIUM STARCH GLYCOLATE
 56
 : 
1. Nonproprietary Names : 
        BP         : Sodium Starch Glycollate 
        Ph Eur   : Carboxymethylamylum natricum 
        USPNF : Sodium starch glycolate 
2. Synonyms :  
        Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; 
starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
3. Chemical Name : 
         Sodium carboxymethyl starch. 
4. Structural Formula : 
              
5. Molecular weight : 
            5×10
5 _ 
1×10
6  
6. Functional Category : 
       Tablet and capsule disintegrant 
7. Applications in pharmaceutical formulation or technology : 
        Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant 
in capsule and tablet formulations. It is commonly used in tablets prepared by either 
direct compression or wet-granulation processes. The usual concentration employed 
in a formulation is between 2% and 8%, with the optimum concentration about 4%, 
although in many cases 2% is sufficient. Disintegration occurs by rapid uptake of 
water followed by rapid and enormous swelling. 
        Sodium starch glycolate has also been investigated for use as a suspending 
vehicle. 
8. Description : 
        Sodium starch glycolate is a white to off-white, odourless, tasteless, free-flowing 
powder.  
9. Typical Proprties : 
        Acidity / alkalinity: pH 3.0–5.0 or pH 5.5–7.5 for a 3.3% w/v aqueous 
dispersion. 
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CROSCARMELLOSE SODIUM 
56
: 
1. Nonproprietary Names : 
        BP         : Croscarmellose sodium 
        PhEur    : Carmellosum natrium conexum 
        USPNF : Croscarmellose sodium 
2. Synonyms :  
        Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol. 
3. Chemical Name : 
        Cellulose, carboxymethyl ether, sodium salt, crosslinked 
4. Empirical Formula : 
        Croscarmellose sodium is a crosslinked polymer of carboxymethylcellulose 
sodium. 
5. Structural Formula : 
                           
6. Molecular weight : 
           90,000–7,00,000. 
7. Functional category : 
         Tablet and capsule disintegrant. 
8. Applications in pharmaceutical formulation or technology  
       Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant  for capsules, tablets. In tablet formulation croscarmellose sodium 
may be used in both direct-compression and wet-granulation processes. 
Croscarmellose sodium at concentrations up to 5% w/w may be used as a tablet 
disintegrant. 
          When used in wet granulations, the croscarmellose sodium should be added 
in both the wet and dry stages of the process (intra- and extragranularly) so that 
the wicking and swelling ability of the disintegrant is best utilized. 
9. Description : 
           Croscarmellose sodium occurs as an odorless, white or grayish white 
powder. 
10. Typical properties : 
    Acidity/alkalinity: pH = 5.0–7.0 in aqueous dispersions. 
    Density (bulk)     : 0.529 g/cm3 for Ac-Di-Sol 
    Density (tapped) : 0.819 g/cm3 for Ac-Di-Sol 
    Density (true)     : 1.543 g/cm3 for Ac-Di-Sol 
    Solubility            : insoluble in water, although croscarmellose sodium rapidly   
                                  swells to 4-8 times its original volume on contact with water. 
                                  Practically insoluble in acetone, ethanol and toluene.        
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CROSPOVIDONE 
56 
:       
1. Nonproprietary Names : 
         BP       : Crospovidone 
         PhEur  : Crospovidonum 
         USPNF: Crospovidone    
2. Synonyms :      
          Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; Polyplasdone 
XL; Polyplasdone XL-10; polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-
pyrrolidinone homopolymer. 
3. Chemical Name : 
           1-Ethenyl-2-pyrrolidinone homopolymer 
4. Empirical Formula : 
           The USPNF 23 describes crospovidone as a water-insoluble synthetic 
crosslinked homopolymer of N-vinyl-2-pyrrolidinone. 
5. Structural Formula : 
                         
6. Molecular weight : 
             (C6H9NO)n >1 000 000 
7. Functional Category : 
             Tablet disintegrant. 
8. Applications in pharmaceutical formulation or technology : 
             Crospovidone is a tablet disintegrant and dissolution agent used at 2–5% 
concentration in tablets prepared by direct-compression or wet- and dry-
granulation methods. It rapidly exhibits high capillary activity and pronounced 
hydration capacity, with little tendency to form gels. 
             Crospovidone can also be used as a solubility enhancer. With the 
technique of co-evaporation, crospovidone can be used to enhance the solubility 
of poorly soluble drugs. 
9. Description : 
             Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odorless or nearly odorless, hygroscopic powder. 
10. Typical properties : 
             Acidity/alkalinity : pH  5.0–8.0 (1% w/v aqueous slurry) 
             Density                 : 1.22 g/cm3 
             Solubility              : Practically insoluble in water and most common 
                                             organic solvents. 
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MANNITOL 
56
: 
1. Nonproprietary Names : 
           BP      : Mannitol 
           JP       : D-Mannitol 
           PhEur : Mannitolum 
           USP   : Mannitol 
2. Synonyms : 
          Cordycepic acid; C*PharmMannidex; E421; manna sugar; D-mannite; mannite; 
Mannogem; Pearlitol. 
3. Chemical Name : 
           D-Mannitol 
4. Emirical Formula : 
           C6H14O6 
5. Molecular weight : 
            182.7 
6. Structural Formula : 
            
         
 
7. Functional Category : 
            Diluent; diluent for lyphilized preparations; sweetening agent; tablet and 
capsule diluent; tonicity agent. 
8. Applications in pharmaceutical formulation or technology : 
            In pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) 
in tablet formulations, where it is of particular value since it is not hygroscopic and 
may thus be used with moisture-sensitive active ingredients. 
             Specific tablet applications include antacid preparations, glyceryl trinitrate 
tablets, and vitamin preparations. Mannitol is commonly used as an excipient in the 
manufacture of chewable tablet formulations because of its negative heat of solution, 
sweetness, and ‘mouth feel’. 
             Given orally, mannitol is not absorbed significantly from the GI tract, but in 
large doses it can cause osmotic diarrhea. 
9. Description : 
             Mannitol occurs as a white, odorless, crystalline powder, or free-flowing 
granules. It has a sweet taste, approximately as sweet as glucose and half as sweet as 
sucrose, and imparts a cooling sensation in the mouth. 
10. Typical properties : 
             Flowability   : Powder is cohesive, granules are free flowing. 
             Melting point: 166–168 0C 
             Solubility      : Soluble in alkalies 
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ASPARTAME 
56
: 
1. Nonproprietary Names : 
       BP        : Aspartame 
       PhEur   : Aspartamum 
       USPNF : Aspartame 
2. Synonyms :      
       3-Amino-N-(a-carboxyphenethyl)succinamic acid N-methyl ester; 3-amino-
N-(a-methoxycarbonylphenethyl)succinamic acid; APM; aspartyl phenylamine 
methyl ester; Canderel;E951; Equal; methyl N-a-L-aspartyl-L-phenylalaninate; 
NutraSweet; Pal Sweet; Pal Sweet Diet; Sanecta; SC-18862;Tri-Sweet. 
3. Chemical Name : 
        N-a-L-Aspartyl-L-phenylalanine 1-methyl ester 
4. Empirical Formula : 
        C14H18N2O5 
5. Molecular Weight : 
         294.31 
6. Structural Formula : 
      
7. Functional Category : 
               Sweetening agent. 
8. Applications in pharmaceutical formulation or technology : 
         Aspartame is used as an intense sweetening agent in pharmaceutical 
preparations including tablets, powder mixes, and vitamin preparations.The 
approximate sweetening power is 180–200 times that of sucrose. Aspartame is 
metabolized in the body and consequently has some nutritive value. 
9.  Description : 
         Aspartame occurs as an off white, almost odorless crystalline powder with 
an intensely sweet taste. 
10. Typical Properties : 
         Acidity/alkalinity : pH  4.5–6.0 (0.8% w/v aqueous solution). 
         Density (tapped)  : 0.29 g/cm3  
         Density (true)      : 1.347 g/cm3 
         Solubility         : slightly soluble in ethanol (95%); sparingly soluble in water 
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MAGNESIUM STEARATE 
56
 : 
1. Nonproprietary Names: 
      BP/JP/USPF : Magnesium stearate. 
      Ph Eur           : Magnesii stearas. 
2. Synonyms: 
      Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
3. Chemical Name : 
       Octadecanoic acid magnesium salt. 
4. Empirical Formula : 
       C36H70MgO4           
5. Molecular weight : 
       591.34 
6. Structural Formula: 
            [CH3(CH2)16COO]2Mg 
7. Functional Category: 
                USP    : Tablet and capsule lubricant. 
             BP/EP : lubricant, pharmaceutical aid. 
             Others : Glidant, anti-adherent. 
8. Applications in pharmaceutical formulation or technology: 
             Tablet and capsule lubricant, glidant or anti-adherent. 
9. Description: 
       Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. 
10. Typical Properties : 
        Density (bulk)   : 0.159 g/cm3 
        Density (tapped): 0.286 g/cm3 
        Density (true)    : 1.092 g/cm3 
        Melting range    : 117–1508C (commercial samples); 
                                   126–1308C (high purity magnesium stearate). 
        Solubility          : Practically insoluble in ethanol, ether and water; slightly     
                                   soluble in warm benzene and ethanol (95%).            
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TALC 
56
 : 
1. Nonproprietary Names 
           BP      : Purified talc                         
           JP       : Talc 
           PhEur : Talcum 
           USP    : Talc 
2.  Synonyms : 
           Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
3. Chemical Name : 
           Talc 
4. Empirical Formula : 
           Talc is a purified, hydrated, magnesium silicate, approximating to the formula 
Mg6(Si2O5)4(OH)4. 
5. Molecular Weight : 
     379.3 g/mol   
6. Functional Category : 
            Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant 
7. Applications in pharmaceutical formulation or technology : 
            Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent. In topical preparations, talc is used as a dusting powder, although it should 
not be used to dust surgical gloves. Talc is additionally used to clarify liquids and is 
also used in cosmetics and food products, mainly for its lubricant properties. 
8. Description : 
             Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
9. Typical properties : 
             Acidity/alkalinity: pH  7–10 for a 20% w/v aqueous dispersion. 
             Solubility            : Practically insoluble in dilute acids and alkalis, 
                                           organic solvents, and water. 
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MATERIALS AND METHODS 
                  Table No:4   List of materials and their applications in formulation 
S.No Name of the materials Use in Formulation 
1. Nizatidine Active ingredient 
2. Eudragit E100 Taste masking agent 
3. Mannitol Diluent 
4. Sodium starch glycolate Superdisingrant 
5. Croscarmellose sodium Superdisingrant 
6. Cross povidone Superdisingrant 
7. Aspartame Sweetener 
8. Mint flavour Flavouring agent 
9. Magnesium stearate Glidant 
10. Talc Lubricant 
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                              Table No:5   Equipments used for the Research Work 
 
S.No Insrtuments Used Manufacturing company 
1. 
Digital Balance Shimatzu LB 300 
2. 
Tablet hardness tester Pfizer hardness tester 
3. 
Friability tester Riche Pharma 
4. 
Vernier Caliper Mitutoyo digimatic caliper 
5. 
Dissolution apparatus USP 
Electrolab tablet dissolution 
apparatus 
6. 
Double beam UV Spectrophotometer Shimatzu UV-1800 
7. 
Rotary tablet punching machine Cadmach 
8. 
pH meter Elico Ll120 
9. 
FT-IR Spectrophotometer KBR press model M15 
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7.1.  PREFORMULATION STUDY: 
         Preformulation studies are the first step in the development of a dosage form. 
Preformulation study relates to pharmaceutical and analytical investigation carried out 
proceeding and supporting formulation development efforts of the dosage form of the drug 
substance. It is an investigation of physicochemical properties of the drug substance alone 
and along with excipients which may influence the formulation design, manufacture methods 
and pharmacokinetic and pharmacodynamic properties of the final product. The following 
preformulation studies were performed on the obtained sample of drug. 
7.1.1.    Melting point: 
         Melting point of the drug was determined by using melting point apparatus. This 
was compared with the official melting point value of drug. 
7.1.2.   Drug and Drug-Excipients physical compatibility studies: 
          To study the physical compatibility of various formulation excipients with 
Nizatidine, solid admixtures were prepared by mixing the drug with excipients 
separately in the ratio of 1:1 and were filled in 2 ml glass vials and sealed. And they 
were kept in stability chamber at room temperature and 30±2
0
C/65±5%RH. The 
samples were withdrawn and analysed for colour change for every 10 days. 
7.1.3. Chemical compatibility studies by FT-IR: 
                  IR spectra of drug, polymer and all superdisintegrants alone and along with  
      drug were taken by using KBr pellet method and scanned at a moderate scanning 
      speed between 4000-400 cm
-1 
using FT-IR. The peak values and the possibility of 
      functional groups shown in spectra were compared with standard values.  
7.1.4. Determination of Analytical Wavelength(λmax): 
      A standard stock solution of Nizatidine was prepared by dissolving accurately 
weighed 5 mg of Nizatidine in water in a 50 ml volumetric flask and the volume was 
made up to 50 ml with water to obtain a stock solution of 100 µg/ml. From the 
standard stock solution, 10 ml was pipetted into 100 ml volumetric flask. The volume 
was made up to 100 ml with water. The resulting solution containing 10 µg/ml was 
scanned between 200 and 400 nm.  
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7.1.5. Calibration curve of Nizatidine : 
1. Preparation of 0.1N HCl : 
           85 ml of conc.HCl was pipetted out into 1000 ml of volumetric flask 
and the volume was made up to 1000 ml with distilled water to prepare 0.1N 
HCl. 
2. Preparation of buffer solution of pH solution: 
a. Preparation of 0.2M NaOH solution: 
       8 g of NaOH was accurately weighed and taken into 1000 ml of 
volumetric flask. Then it was dissolved in little amount of water and the 
volume was made up to 1000 ml with distilled water to prepare 0.2M 
NaOH solution. 
b. Preparation of 0.2M potassium di hydrogen phosphate solution: 
       27.218 g of potassium di hydrogen phosphate was accurately weighed 
and taken into 1000 ml of volumetric flask. Then it was dissolved in little 
amount of water and the volume was made up to 1000 ml with distilled 
water to prepare 0.2M potassium di hydrogen phosphate solution. 
3. Calibration curve of Nizatidine in 0.1N HCl: 
         Accurately weighed quantity of Nizatidine (5 mg) was dissolved in little 
quantity of 0.1N HCl and volume was made up to 50 ml with the same ( 100 
µg/ml). Then withdraw 1, 2, 3, 4, 5 ml from the above solution in to separate 
50 ml volumetric flasks and made up the volume to 50 ml to produce 2, 4, 6, 
8, 10 µg/ml respectively. And the absorbances were taken at 315 nm. This 
procedure was performed in triplicate to validate the calibration curve. 
4. Calibration curve of Nizatidine in buffer solution of pH 6.8 : 
         Accurately weighed quantity of Nizatidine (5 mg) was dissolved in little 
quantity of pH 6.8 buffer solution and volume was made up to 50 ml with the 
same (100 µg/ml). Then withdraw 1, 2, 3, 4, 5 ml from the above solution in to 
separate 50 ml volumetric flasks and made up the volume to 50 ml to produce 
2, 4, 6, 8, 10 µg/ml respectively. And the absorbances were taken at 315 nm. 
This procedure was performed in triplicate to validate the calibration curve. 
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7.2  TASTE MASKING OF NIZATIDINE: 
7.2.1 Introduction: 
            Nizatidine is an anti-ulcer agent, prescribed extensively both in solid and liquid 
dosage forms and is extensively bitter resulting in poor patient compliance. Complexation 
with Eudragit E100 is efficient technique of masking the bitterness. 
            The purpose of this research was to formulate tasteless complexes of Nizatidine with 
Eudragit E100 ( about polymer).  
7.2.2. PREPARATION OF DRUG POLYMER COMPLEX (DPC): 
            The drug polymer complex (DPC) was prepared by using different ratios of 
Nizatidine and Eudragit E100 i.e. 1:1, 1:2, 1:3, 1:4 and 1:5 were mixed by using mortar and 
pestle. The mixture of drug and polymer was slowly added with continuous stirring (600 
rpm) into a 500ml of glass beaker containing 10% ethanol till a gel was formed. The gel was 
manually pressed out using a syringe, on a polycarbonate sheet. After extrusion of the gel, 
ethanol was allowed to evaporate overnight at room temperature and vacuum dried at -700 
mm of Hg at 35
0
C for 6 hr. The sample was then grounded in a mortar and pestle, and again 
vacuum dried under the aforementioned conditions to ensure adequate solvent removal. The 
prepared taste masked granules was used for further studies. 
7.2.3. CHARACTERIZATION OF DPC (Drug polymer complex): 
7.2.3.1. Differential Scanning Colorimetery (DSC) Study: 
           DSC is a technique in which the difference in heat flow between the sample and a 
reference is recorded versus temperature. DSC thermal analytical profile of a pure chemical 
represents its product identity. By comparing the DSC curves of a pure drug sample with that 
of formulation, the presence of an impurity due to the interaction of polymer and drug can be 
detected in a formulation. The scanning temperature for pure drug and formulation are the 
same when dynamic measurements are performed, and hence the required heat energy for 
chemical transformation is directly recorded on a heat flow versus temperature graph. The 
energy is measured as Joules per kilocalorie. All dynamic DSC studies were carried out on 
TA instruments Q200 series. The instrument was calibrated using high purity indium metal as 
standard. The dynamic scans were taken in nitrogen atmosphere at the heating rate of 
10ºC/min. 
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7.2.3.2. Determination of drug content 
16
: 
           DPC equivalent to 75 mg of drug was stirred by using magnetic stirrer with 100 ml of 
0.1 N HCl for 60 minutes, till the entire drug leached out from complex, then the solution was 
filtered through whatman filter paper. Further, solution diluted with 0.1 N HCl and the drug 
content was determined spectrophotometrically at 315 nm. As the concentration of Eudragit 
E100 increases the drug content of the complex has been increased. 
7.2.3.3. In Vitro taste evaluation 
16
: 
           In Vitro taste was evaluated by determining the drug release from the complex into 
simulated salivary fluid (SSF) (pH 6.8) to predict release of drug in the human saliva. DPC, 
equivalent to 10 mg of Nizatidine (equivalent to dose 75 mg), was placed to 10 ml screw 
capped bottles containing SSF and fixed in water bath shaker and shaken for 60 sec at 50 
rpm. The amount of drug released was analyzed at 315 nm. As the concentration of the 
Eudragit E100 increases, the release of the drug from the complex in the SSF has been 
decreased which indicates that the taste has been masked. 
   Table No:6  Effect of different concentrations of Drug-Eudragit E100 on drug content   
and In Vitro taste evaluation. 
Drug- 
polymer 
ratio 
% Drug content* %Drug dissolved in 
SSF* 
Taste 
1:1 98.57±0.42 0.83±0.12 Bitter 
1:2 98.62±0.38 0.64±0.06 Bitter 
1:3 98.94±0.36 0.37±0.02 Slightly bitter 
1:4 99.28±0.15 0.12±0.03 No bitter 
1:5 99.46±0.12 ND No bitter 
                *Results are the mean of 3 observations ± SD 
                  ND – Not detectable 
 
 
 
 
 
 
                                                                       MATERIALS AND METHODS 
 
Nandha College Of Pharmacy, Erode Page 46 
 
7.3 FORMULATION OF NIZATIDINE ODTs: 
      Label claimed : 450 mg 
      Batch size       : 100 tablets 
      Punch size      : 10 mm concave punch 
                          Table No: 7   Formulation of Nizatidine ODTs 
Ingredients 
for one tablet 
F1 
mg 
F2 
mg 
F3 
Mg 
F4 
mg 
F5 
mg 
F6 
mg 
F7 
mg 
F8 
mg 
F9 
mg 
DPC (equivalent to 75mg of 
Nizatidine) 
377 377 377 377 377 377 377 377 377 
Mannitol 51 46.5 37.5 51 46.5 37.5 51 46.5 37.5 
Crosspovidone  9 13.5 22.5 - - - - - - 
Croscarmellose sodium - - - 9 13.5 22.5 - - - 
Sodium starch glycolate - - - - - - 9 13.5 22.5 
Aspartame 4 4 4 4 4 4 4 4 4 
Mint Flavour 3 3 3 3 3 3 3 3 3 
Magnesium stearate 3 3 3 3 3 3 3 3 3 
Talc 3 3 3 3 3 3 3 3 3 
Total weight 450 450 450 450 450 450 450 450 450 
 
DPC – Drug Polymer Complex 
 
 
 
 
 
 
                                                                       MATERIALS AND METHODS 
 
Nandha College Of Pharmacy, Erode Page 47 
 
7.4 PREPARATION OF TABLETS: 
In - House Specification: 
    The Nizatidine orodispersible tablets should have following criteria. 
                    Table No:8   In house specification of Nizatidine orodispersible tablets 
S.No Parameter Specification 
1. Theoretical weight per tablet (mg) 450 mg 
2. Average weight of 20 tablets (mg) 450 mg 
3. Uniformity of weight (mg) 450 mg 
4. Thickness (mm) 5.5 mm 
5. Hardness (Kg/cm
2
) 3-4 Kg/cm
2 
6. Friability (%) Not more than 1 % 
7. Disintegration time (sec) Not more than 3 min 
8. Dissolution (%) Not less than 80 % in 10 min 
 
            In the present study Direct Compression technique was employed for the preparation 
of orodispersible tablets.  
            Direct compression is widely used in tableting because it requires fewer processing 
steps, simpler to validate and improves drug stability when compared with the wet 
granulation method. Direct compression also eliminates exposure to heat and moisture during 
processing and is a more economical process. However, the majority of active pharmaceutical 
ingredients exhibit poor compressibility. Therefore the addition of directly compressible 
adjuvant is mandatory in such cases. 
 Directly compressible filler should exhibit good flowability and compactibility. Good 
flowability is necessary to ensure rapid and uniform die filling, whereas high compactibility 
is necessary to produce tablets having sufficient mechanical strength. 
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Precautions:
 
1. Inspection of cleanliness of the compression machine. 
2. Inspection of cleanliness of storage container. 
3. Inspection of cleanliness of all the Mechanical stirrers and weighing balance. 
MANUFACTURING PROCEDURE: 
Step 1: Optimized batch of drug polymer complex equivalent to 75 mg of Nizatidine was   
             used for the ODT preparation. 
Step 2: Mannitol, crospovidone/ Croscarmellose sodium/ sodium starch glycolate and 
             aspartame were weighed individually and passed through #40 mesh. 
Step 3: All the above sifted excipients were mixed with the optimized DPC and mixed  
             properly for 3 min and mint flavour was added and mixed properly. 
Step 4:  Finally magnesium stearate and talc were added to the mixture thoroughly for 2 min. 
Step 5:  The powder blend was compressed by using 10 mm concave punch. 
7.5 PRE COMPRESSION STUDIES ON GRANULES: 
7.5.1. Bulk density: 
               It is also called as the poured density. It is the ratio of total mass of powder to the 
bulk volume of powder. It was measured by pouring the 20 g powder (passed through 
standard sieve # 20) into a 100 ml measuring cylinder and initial volume was noted. This 
initial volume is called the bulk volume. From this the bulk density is calculated according to 
the formula mentioned below. It is expressed in g/ml and is given by 
                                         Db = M/ Vb 
                      Where, M is the mass of powder 
                                   Vb is the bulk volume of the powder. 
7.5.2. Tapped density: 
             It is the ratio of total mass of the powder to the tapped volume of the powder. 
Volume was measured by tapping the powder for 750 times and the tapped volume was 
noted, if the difference between these two volumes is less than 2%. If it is more than 2%, 
tapping is continued for 1250 times and tapped volume was noted. Tapping was continued 
until the difference between successive volumes is less than 2 % (in a bulk density 
apparatus). It is expressed in g/ml and is given by 
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                                                     Dt = M / Vt 
                                       Where, M is the mass of powder 
                                                  Vt is the tapped volume of the powder. 
7.5.3. Angle of repose (θ): 
             The friction forces in a loose powder can be measured by the angle of repose (q). It is 
an indicative of the flow properties of the powder. 
             It is defined as maximum angle possible between the surface of the pile of powder 
and the horizontal plane and it can be calculated by the following formula. 
                                                  tan (θ) = h / r 
                                                  θ = tan-1 (h / r) 
                                        Where, θ is the angle of repose. 
                                                     h is the height in cms 
                                                     r is the radius in cms. 
             The powder mixture was allowed to flow through the funnel fixed to a stand at 
definite height (h). The angle of repose was then calculated by measuring the height and 
radius of the heap of powder formed. Care was taken to see that the powder particles slip and 
roll over each other through the sides of the funnel. Relationship between angle of repose and 
powder flow property is given as follows. 
           Table No.9   Angle of Repose as an Indication of Powder Flow Properties 
S.No Angle of Repose (θ) Type of Flow 
1. < 20 Excellent 
2. 20 – 30 Good 
3. 30 – 34 Passable 
4. > 34 Very Poor 
7.5.4. Carr’s index (or) % compressibility: 
             It indicates powder flow properties. It is expressed in percentage and is give 
                                                 Dt – Db 
                                         I = ------------ × 100 
                                                    Dt 
                            Where, Dt is the tapped density of the powder and 
                                       Db is the bulk density of the powder. 
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              Table No.10     Relationship between % compressibility and flow ability 
S.No % Compressibility Flow ability 
1. 5-12 Excellent 
2. 12-16 Good 
3. 18-21 Fair Passable 
4. 23-35 Poor 
5. 33-38 Very Poor 
6. <40 Very Very Poor 
 
7.5.5. Hausner ratio: 
            Hausner ratio is an indirect index of ease of powder flow. It is calculated by the 
following formula. 
                                                                       Dt 
                                         Hausner ratio = ------- 
                                                                       Db 
                                      Where, Dt is the tapped density. 
                                                   Db is the bulk density. 
            Lower hausner ratio (<1.25) indicates better flow properties than higher ones (>1.25). 
7.6 POST COMPRESSION STUDIES OF TABLETS: 
7.6.1. Description: 
             The general appearance of the tablet like size, shape, and colour should be observed. 
It must need for consumer acceptance and during storage physical chances may happens it 
easily matched with description. 
7.6.2. Weight variation: 
             Weigh individually 20 tablets taken at random and determine the average weight. Not more 
than 2 of the individual weight deviate from the average weight. The percentage deviation limits 
shown in the following table. 
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                    Table No.11   Weight Variation Specification as per IP 
S.No Average weight of tablet % Deviation 
1. 80 mg or less ±10 
2. More than 80 mg but less 
than 250 mg 
±7.5 
3. 250 mg or more ±5 
 
7.6.3. Thickness: 
           It can be dimensionally described and controlled. Thickness may affect the hardness, 
disintegration time and dissolution rate. Tablet thickness of 10 tablets was measured by 
vernier callipers. 
7.6.4. Hardness: 
          Tablet requires certain amount of strength or hardness to withstand mechanical shocks 
of handling in manufacture, packing and shipping. Hardness or tablet crushing strength (fc ) 
is the force required to break a tablet in a diametric compression was measured using 
Monsanto tablet hardness tester. It is expressed in kg/cm2. 
7.6.5. Friability: 
           The crushing test may not be the best measure of potential behaviour during handling 
and packaging. The resistance to surface abrasion may be a more relevant parameter. 
Friability of each batch was measure in “Electro lab Friabilator”. Five preweighed tablets 
were rotated at 25 rpm for 4 min, the tablets were then re weighed and the percentage of 
weight loss was calculated. It should be less than 1%. 
                                                        Winitial - Wfinal 
                                                  F = --------------------- ×100 
                                                             Winitial 
Rapidly Disintegrating Property: 
To evaluate the tablets for their rapid disintegration properties, following tests were carried 
out. 
7.6.6. Wetting time: 
           Wetting time is closely related to the inner structure of the tablets and to the 
hydrophilicity of the excipients.  
           The procedure for wetting time is as follows, a piece of tissue paper folded double was 
placed in a Petri plate (internal diameter is 6.5 cm) containing 6ml of water containing eosin 
(water soluble dye). The tablet was placed on the paper and the time for complete wetting of 
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the tablet was measured in seconds. This has been repeated three times for each formulation 
to get accurate value. 
7.6.7. Modified disintegration test: 
           The standard procedure of performing disintegration test for these dosage forms has 
several limitations and they do not suffice the measurement of very short disintegration times. 
The disintegration time for ODT needs to be modified as disintegration is required without 
water, thus the test should mimic disintegration in salivary contents. For this purpose, a 
petridish (10 cm diameter) was filled with 10 ml of water. The tablet was carefully put in the 
centre of petridish and the time for the tablet to completely disintegrate into fine particles was 
noted. 
7.6.8. Water absorption Ratio: 
           A piece of tissue paper folded twice was placed in a small Petri dish containing 6 ml of 
water. A tablet was put on the paper & the time required for complete wetting was measured. 
The wetted tablet was then weighed. Water absorption ratio, R, was determined using 
following equation, 
                                           R=10(wa/wb)  
               where, Wb is weight of tablet before water absorption  
                           Wa is weight of tablet after water absorption. 
7.6.9. In Vitro dispersion time: 
          Tablet was added to 10 ml of SSF (phosphate buffer solution) ph 6.8 at 37+0.5ºc, time 
required for complete dispersion of a Tablet was measured. 
7.6.10. In Vitro drug release:   
           In Vitro dissolution test was carried out by triplicate method using USP Type II 
(paddle type) apparatus. 900 ml of SGF (0.1N HCl) to maintain ph 1.2 was used as 
dissolution medium, and the paddle was rotated at 50 rpm for 1hr at a temperature of 37
0
C. 
Sampling was done at regular intervals and was replaced by 0.1N HCl after each sampling 
interval. The samples are then analysed spectrophotometrically at 315 nm. 
7.6.11. Content uniformity test: 
          Standard solution: Prepare a solution of Nizatidine in water having a known 
concentration of about 0.9 µg/ml. 
           Sample solution: 20 tablets were randomly selected from the prepared batch and 
triturated to get fine powder. Powder equivalent to total weight of the tablet was taken and 
dissolved in beaker containing small amount of water and shake for some time. Filter the 
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solution to 500 ml volumetric flask and make up the volume with water. And add 1 ml of this 
solution to 100 ml volumetric flask and make up the volume with water. Take the absorbance 
at 315 nm using water as a blank for background correction.  
7.6.12. Stability study: 
        FDA and ICH specifies, the guidelines for stability testing of a new drug product, as a 
technical requirement for the registration of a pharmaceuticals for human use. 
        The ICH triplicate guidelines have established that long term stability testing should be 
done at 25
0
C / 60% RH for 12 months. Accelerated stability testing should be done at 40
0
C / 
75% RH for six months. Stability testing at intermediate storage condition should be done at 
30
0
C / 65%RH. Different storage conditions and periods of stability testing are shown in the 
Table No.12. 
                                Table No.12    ICH Guidelines for stability study 
Study Storage condition Duration 
Long term 25
0
C±2
0
C, 60%±5% RH 12 months 
Intermediate 30
0
C± 2
0
C, 65%± 5% RH 6 months 
Accelerated temperature 40
0
C± 2
0
C, 75%± 5% RH 6 months 
 
         In the present work, stability study was carried out for Nizatidine ODT of desirable 
formulation of 75 mg label claim. 
         Any ideal dosage form apart from other dosage form requirement should provide 
consistency of drug content and release throughout its shelf life. 
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RESULTS AND DISCUSSION 
8.1. PREFORMULATION STUDIES: 
          The overall objective of Preformulation studies is to generate useful information to the 
formulator on developing stable and bioavailable dosage forms that can be mass produced. 
8.1.1. Determination of melting point of Nizatidine: 
            Melting point of Nizatidine was determined by capillary method and was found to be 
132.7
0
C which is in the range specified in the official limits. 
8.1.2. Determination of analytical wavelength (λmax) of Nizatidine: 
            By using UV-Spectrophotometer Nizatidine drug solution in water was scanned 
between the range of 200-400 nm using water as the blank and a sharp peak was observed at 
315 nm which reports that the analytical wavelength is 315 nm. The value found was lies in 
the range specified in official monograph and it has shown in Fig No.6. 
                                         Fig No.6.  λmax of Nizatidine 
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8.1.3. Physical compatibility studies of drug and excipients: 
             Physical compatibility study of drug and excipients is necessary for the stable and 
effective solid dosage form which is performed on visual basis. The study reveals that the 
drug, polymer and other excipients were physically compatible with one another as there was 
no change in physical description. The results have been illustrated in Table No.13. 
 8.1.4. Chemical compatibility studies by FTIR: 
          The IR spectral analysis of the Nizatidine, polymer and other excipients was carried out 
by using KBr pellet method and the spectra were shown from Fig No.7 to Fig No.15. All the 
characteristic peaks appear for the pure Nizatidine and its physical mixture indicating no 
interaction between Nizatidine and excipients. 
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          Table No.13    Physical compatibility studies of drug and excipients 
S.No Drug + Excipients Description at initial day RT, 
35±2
0
C/65±5% 
RH    IN days 
10
th 
20
th 
30
th 
1. NZ Off white to brown crystalline powder NC NC NC 
2. EE100 Colourless to yellow tinged granules NC NC NC 
3. CP White, crystalline powder NC NC NC 
4. CCS White or greyish white powder NC NC NC 
5. SSG White, free-flowing hygroscopic powder NC NC NC 
6. NZ + EE100 Off white to brown free flowing powder NC NC NC 
7. MNT Free flowing white crystalline powder NC NC NC 
8. APT Off white, crystalline powder NC NC NC 
9. MF Yellow colour liquid NC NC NC 
10. Mg.S White, crystalline powder NC NC NC 
11. Talc White or greyish white powder NC NC NC 
12. NZ + CP Off white to yellow powder NC NC NC 
13. NZ + CCS Off white to yellow powder NC NC NC 
14. NZ + SSG Off white to yellow powder NC NC NC 
15. NZ + ALL Off white to yellow free flowing powder NC NC NC 
   NZ – Nizatidine, EE100 – Eudragit E100, CP – Crosspovidone, CCS – Croscarmellose 
sodium, SSG – Sodium starch glycolate, MNT – Mannitol, APT – Aspertame, MF – Mint 
flavour, Mg. S – Magnesium stearate, NC – No change. 
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Chemical compatibility studies by FT-IR: 
Fig No.7. Nizatidine 
 
Fig No.8.Eudragit E100 
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Fig No.9. Nizatidine + Eudragit E100 
 
Fig No.10.Crospovidone 
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Fig No.11. Cros carmellose sodium 
 
Fig No.12. Sodium starch glycolate 
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Fig No.13. Nizatidine + Crospovidone 
 
Fig No.14. Nizatidine + Croscarmellose sodium 
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Fig No.15. Nizatidine + Sodium starch glycolate 
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8.1.3. CALIBRATION CURVE OF NIZATIDINE: 
         The absorbances of solution of Nizatidine in 0.1N HCl and in pH 6.8 buffer solution at 
315 nm have been taken and it was found that the solutions show linearity in absorbance at a 
concentration of 0-10 µg/ml and obey beer-lamberts law. The values are illustrated in Table 
No.14 & Fig No.16, 17.  
                          Table No.14    Calibration curve of Nizatidine 
S.No Concentration 
(µg/ml) 
Absorbance at λ 315 nm 
(0.1N HCl) 
Absorbance at 315 nm 
(pH 6.8 buffer solution) 
1. 0 0 0 
2. 2 0.193 0.165 
3. 4 0.392 0.331 
4. 6 0.584 0.498 
5. 8 0.771 0.663 
6. 10 0.940 0.827 
 
                   Fig No.16.  Linearity of Nizatidine calibration curve in 0.1N HCl 
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        Fig No.17.  Linearity of Nizatidine calibration curve in pH 6.8 buffer solution 
                  
8.1.4. Differential Scanning Colorimetry (DSC) Study of DPC: 
                                       Fig No.18.  DSC thermogram of Nizatidine 
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                                  Fig No.19. DSC thermogram of Eudragit E100 
 
                       Fig No.20. DSC thermogram of Drug polymer complex         
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                   DSC analysis of Nizatidine, Eudragit E100 and DPC were carried out to check 
any changes in thermal properties of Nizatidine due to complexation with Eudragit E100. The 
DSC thermogram of Nizatidine was a single, sharp exotherm at 133.13
0
C (Fig No.17). In 
case of DPC, the DSC thermogram was shortened exothermic peak appears at 130.71
0
C (Fig 
No.19) which may be due to ethanol dissolution state. Thus it was showed that there were no 
major difference in DSC thermograms of Nizatidine and DPC, therefore the Eudragit E100 is 
compatible with the drug and so could be safely used to formulate ODTs.      
8.2. PRE COMPRESSION STUDIES ON POWDER BLEND: 
8.2.1. Bulk density: 
            The bulk density of the formulation mixture of drug with different superdisintegrants 
was measured by graduated cylinder. The bulk density was found in the range from 0.5 – 
0.522 g/ml. The results are illustrated in Table No.15. 
8.2.2. Tapped density: 
            The tapped density of the formulation mixture of drug with different 
superdisintegrants was measured by measuring cylinder. The tapped density was found in the 
range of 0.583 – 0.598 g/cm3.The results are shown in Table No.15. 
8.2.3. Compressibility index: 
           Compressibility index (Carr’s index) indicates the flow property of the granules or the 
powders. Flow property plays a major role in the dosage forms especially in tablet dosage 
forms because improper flow of powders or granules may cause weight variation. Values of 
compressibility index below 15% indicate good flow whereas the values above 15% indicate 
poor flow property.  The compressibility index of various formulation mixture of drug with 
different superdisintegrants was calculated by using bulk density and tapped density results 
and it was found in the range of 12.35 – 13.58 % which reveals that the formulations exhibit 
good flow property. The results are shown in the Table No.15. 
8.2.4. Hausner ratio: 
           It is an indirect index of ease of powder flow. Lower Hausner ratio i.e., <1.25 specifies 
good flow property than the higher Hausner ratio i.e., >1.25. The Hausner ratio of various 
formulation mixture of drug with different superdisintegrants was calculated by using bulk 
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density and tapped density data. It was found in the range of 1.2 – 1.18 which designates that 
that the formulation powders having better flow properties. The results are shown in Table 
No.15. 
8.2.5. Angle of repose (θ): 
         Angle of repose is direct index of the flow property. The angle of repose of various 
formulation blends of drug with different superdisintegrants was measured by using funnel 
method. The range of results is lie in between the 21.8 – 23.270 which indicates that the 
powders having good flow property. The results are illustrated in Table No.15. 
                          Table No.15      Pre compression study of all formulations 
Formulation Bulk 
density* 
g/ml 
Tapped 
density*  
g/ cm
3 
Compressibility 
index* 
Hausner 
ratio* 
Angle of 
repose ()* 
 
F1 0.53±0.15 0.62±0.12 12.35±0.09 1.14±0.05 22.5±0.27 
F2 0.51±0.19 0.6±0.17 13.40±0.14 1.13±0.04 24.7±0.17 
F3 0.57±0.21 0.65±0.21 12.48±0.08 1.06±0.08 25.9±0.21 
F4 0.54±0.26 0.62±0.24 13.40±0.11 1.13±0.06 24.6±0.14 
F5 0.62±0.23 0.69±0.22 12.50±0.12 1.13±0.04 23.5±0.19 
F6 0.58±0.22 0.66±0.13 13.36±0.09 1.10±0.05 26.3±0.28 
F7 0.54±0.14 0.61±0.19 13.46±0.07 1.16±0.07 24.2±0.22 
F8 0.52±0.17 0.59±0.17 13.58±0.10 1.14±0.09 25.4±0.16 
F9 0.59±0.12 0.68±0.14 13.26±0.12 1.18±0.05 26.3±0.23 
                *Results are the mean of 3 observations ± SD 
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8.3. POST COMPRESSION STUDIES: 
8.3.1. Weight variation: 
           Prepared tablets were evaluated for the weight variation and results are depicted in 
Table No.16. The percentage deviation of the weight was within 5% as per monograph. 
8.3.2. Hardness: 
            The hardness of the various formulations was depicted in Table No.16. The hardness 
of the tablets was found in the range of 3.13 – 3.4 Kg/cm2 which is sufficient to withstand 
mechanical shocks of handling in manufacture, packing and shipping. The results have been 
showed that the increase in concentration of the superdisintegrants have no effect on the 
hardness of the tablets. 
8.3.3. Thickness: 
           Thickness is important parameter in packing of tablets and acceptance. The thickness 
of the various tablet formulations was shown in Table No.16. The thickness of the tablet was 
found in the range of 5.13 – 5.72 mm which are sufficient for acceptance and packing. 
8.3.4. Friability:  
            Friability value of tablets specifies resistance of the tablet to surface abrasion. The 
value of friability must be less than 1% for better resistance. The friability of the various 
tablet formulations was shown in the Table No.16. The friability of the tablet was found in 
the range of 0.447 – 0.493 %. The values are within the limit of official monograph i.e., <1%. 
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                      Table No.16   Post compression parameters of all formulations 
Formulation Average weight 
variation*  
Hardness* 
(Kg/cm
2
) 
Thickness* 
(mm) 
Friability* 
(%) 
F1 454±0.12 3.20±0.27 5.13±0.04 0.44±0.05 
F2 451±0.16 3.30±0.34 5.46±0.05 0.46±0.08 
F3 449±0.16 3.30±0.38 5.72±0.02 0.44±0.04 
F4 449±0.09 3.13±0.29 5.27±0.03 0.49±0.07 
F5 455±0.13 3.20±0.36 5.29±0.04 0.46±0.06 
F6 453±0.18 3.33±0.32 5.35±0.03 0.46±0.04 
F7 452±0.09 3.26±0.28 5.58±0.02 0.47±0.09 
F8 454±1.15 3.36±0.33 5.71±0.04 0.44±0.06 
F9 452±1.17 3.40±0.31 5.65±0.05 0.46±0.07 
                *Results are the mean of 3 observations ± SD 
Rapidly disintegrating property: 
8.3.5. Wetting time: 
           The wetting time of tablets indicates the inner structure of the tablets and the 
hydrophilicity of the excipients which should be in the range of sec. The wetting time of the 
various formulations was illustrated in the Table No.17. The values were found in the range 
of 29 – 41.6 sec and designate that all the superdisintegrants having good hydrophilicity.  
8.3.6. Modified disintegration test: 
           The disintegration is prior step for the dissolution of a tablet and was performed by a 
method which is stated under the materials and methods. The modified disintegration time of 
the various formulations was depicted in the Table No.17 and the values are lies in range of 
34 – 43.6 sec. Among all the formulations F3 has shown lower disintegration time which 
contains the 5% of sodium starch glycolate. From the results obtained it has shown that with 
the increasing concentration of superdisintegrant the disintegration time has been decreased. 
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8.3.7. Water absorption ratio: 
           It is important criteria for understanding the capacity of disintegrants to swell in the 
presence of water. The water absorption ratio of the various formulations was depicted in the 
Table No.17. The results are lies in the range of 25.31 – 29.2. The formulations containing 
low concentration of superdisintegrants shows lower water absorption ratio compare to 
formulations containing higher concentration of superdisintegrants, which may be because of 
less swelling property. 
8.3.8. In Vitro dispersion time: 
           The In Vitro dispersion time is measured by the time taken to undergo uniform 
dispersion. The In Vitro dispersion time of the various formulations was shown in the Table 
No.17. The results are lies in the range of 62 – 77 sec. The results showed that the 
crospovidone is the best superdisintegrant which may be because of showing less swelling 
efficiency, high water uptake capacity and spongy nature which yields porous tablet that 
disperse in a matter of seconds. And the results also showed that as the concentration of 
superdisintegrant increases the In Vitro dispersion time decreases. The relation between them 
has been shown in the below figures 20, 21, 22. 
                    Table No.17    Rapidly disintegrating property of all formulations 
Formulation Wetting 
time* 
(sec) 
In Vitro 
Disintegration     
time* (sec) 
Water 
absorption 
ratio* 
In Vitro 
dispersion 
time* (sec) 
% Drug 
content* 
F1 38.0±1.2 41.0±0.3 25.31±1.56 73.3±0.53 99.56±0.54 
F2 34.6±1.8 40.3±0.4 26.46±1.02 70.3±0.42 99.72±0.63 
F3 29.0±1.6 34.0±0.2 29.00±1.45 62.0±0.65 99.88±0.58 
F4 34.6±1.4 43.6±0.5 26.18±1.12 77.0±0.73 99.16±0.51 
F5 41.3±1.3 42.6±0.3 26.30±1.34 67.3±0.43 99.45±0.62 
F6 33.3±1.7 37.6±0.1 27.22±1.52 64.0±0.71 99.61±0.69 
F7 41.6±1.5 43.3±0.2 26.20±1.62 76.0±0.83 99.29±0.43 
F8 37.0±1.6 39.6±0.6 27.01±1.89 72.0±0.59 99.48±0.58 
F9 33.3±1.4 38.3±0.3 29.20±1.01 67.6±0.63 99.57±0.66 
            *Results are the mean of 3 observations ± SD 
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Fig No.21. Comparitive graph of Concentration and In Vitro Dispersion time of F1, F2, 
F3 
                     
Fig No.22. Comparitive graph of Concentration and In Vitro Dispersion time of F4, F5, 
F6 
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Fig No.23. Comparitive graph of Concentration and In Vitro Dispersion time of F7, F8, 
F9 
                     
8.3.9. In Vitro drug release: 
           In Vitro release of various formulations was studied and was shown in the Table 
No.18. The drug release of formulations F1 to F9 is 94.7%, 95.6%, 99.5%, 91.9%, 94.2%, 
96.4%, 90.0%, 92.6%, 94.8% of Nizatidine at the end of 15 min respectively. The fast 
dissolution of all the formulations is might be due to quick disintegration of the tablets to fine 
particles and rapid absorption. Thus formulation F3 showed maximum drug release i.e., 
98.5% at the end of 15 min which contains 5% of the crospovidone as superdisintegrant 
compared to other formulations containing sodium starch glycolate and croscarmellose 
sodium. It might be due to more gelling tendency and low water uptake of Croscarmellose 
sodium and more swelling tendency and sustained release action of sodium starch glycolate. 
The drug release profile of all the individual formulations have been shown from fig 23 to 31. 
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                      Table No.18   In Vitro drug release profile of all formulations 
Formulation In Vitro % drug release in different time intervals (min) 
3 6 9 12 15 
F1 64.3±0.92 71.8±0.85 80.5±0.97 87.6±1.05 94.7±0.89 
F2 66.5±1.16 72.0±1.04 79.1±0.83 86.2±0.96 95.6±0.75 
F3 69.6±0.91 72.0±1.12 78.3±0.86 89.4±1.08 99.5±1.15 
F4 68.0±0.88 71.7±0.92 78.0±0.97 85.6±1.12 91.9±0.78 
F5 69.7±1.08 73.4±1.14 79.0±0.97 87.0±0.94 94.2±0.81 
F6 68.2±1.16 71.0±0.96 76.3±0.98 88.2±1.08 96.4±1.11 
F7 65.1±0.95 70.1±0.89 76.4±1.03 84.5±1.13 90.0±0.91 
F8 67.3±0.89 72.0±0.92 79.0±0.87 86.5±1.06 92.6±0.86 
F9 68.1±1.04 74.5±1.02 79.6±0.93 88.9±1.03 94.8±0.92 
 
                        
                           Fig No.24. Dissolution profile of Formulation F1 
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                                   Fig No.25. Dissolution profile of Formulation F2  
              
                               
                                 Fig No.26. Dissolution profile of Formulation F3          
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                                   Fig No.27. Dissolution profile of Formulation F4 
 
              
                                   
                                Fig No.28. Dissolution profile of Formulation F5 
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                                 Fig No.29. Dissolution profile of Formulation F6 
              
                              
                            Fig No.30. Dissolution profile of Formulation F7 
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                               Fig No.31. Dissolution profile of Formulation F8 
              
                            
                            Fig No.32.  Dissolution profile of Formulation F9 
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                        Fig No.33. Comparitive dissolution profile of F1,F2, F3 
              
                          
                       Fig No.34. Comparitive dissolution profile of F4, F5, F6 
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                           Fig No.35. Comparitive dissolution profile of F7, F8, F9 
              
Fig No.36. Comparitive dissolution profile of all formulations     
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8.3.10. Drug content: 
           The percentage drug content of various formulations has been shown in the Table 
No.17 and the range of content uniformity lies between 99.16 to 99.88 %. 
8.3.11. Stability study: 
            The formulation F3 were kept for accelerated stability study at 40±2
0
C and 75±5% 
RH for one month in stability chamber. After a period of two months, the samples were 
observed for any change in physical parameters. It was observed, no change in colour, taste 
and was also noted that tablets were free of any kind of bad odour. 
           Results obtained from the evaluation after stability study of Nizatidine ODT are shown 
in Table No.19. 
    Table No.19    Evaluation parameters obtained after stability study of the Nizatidine 
ODT (2 months). 
S.No Parameters Units F3 
15 Days 30 Days 45 Days 60 Days 
1. Taste As per 
specifications 
Not bitter Not bitter Not bitter Not bitter 
2. Hardness Kg / cm
2 
3.30±0.41 3.28±0.35 3.25±0.45 3.24±0.28 
3. Friability % w/w 0.44±0.38 0.45±0.25 0.43±0.41 0.42±0.32 
4. Disintegration 
time 
Sec 35.0±0.4 34.6±0.2 34.1±0.5 33.4±0.2 
5. Wetting time Sec 28.0±1.8 27.3±0.3 26.8±0.1 26.3±0.3 
6. Assay % 99.88±0.5 99.54±0.7 99.20±0.3 98.8±0.4 
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SUMMARY AND CONCLUSION 
              ODTs are developed to avoid the choking problems which occur generally with the 
tablet dosage forms. The ODTs disintegrate within fraction of seconds in the mouth without 
need of water and shows maximum drug release within few min and shows immediate effect.  
               Nizatidine is an anti-histaminic drug which reversibly and competitively blocks 
histamine at H 2 receptors, particularly those in gastric parietal cells, antagonising the usual 
stimulatory effect of endogenous histamine on gastric acid production. 
               The present research is directed towards the development of Formulation and 
evaluation of orodispersible tablets of taste masked Nizatidine to improve the 
bioavailability of Nizatidine which shows 70%. As the Nizatidine is bitter in taste, taste 
masking has been done by using a polymer Eudragit E100 which is a cationic copolymer 
based on dimethylaminomethyl methacrylate, butyl methacrylate and methyl methacrylate by 
mass extrusion method. The drug polymer interaction was studied by DSC and the results 
showed no interaction between them.  
               The ODTs of various batches were prepared by using various concentrations of 
various superdisintegrants like sodium starch glycolate, crospovidone and croscarmellose 
sodium by direct compression method.   
                In the present work nine formulations were prepared using mannitol as diluent, 
aspertame as sweetner, and talc as glidant. 
               Characterization of the drug was done by performing the melting point, UV 
spectroscopy and IR spectroscopy. IR spectrum of the pure drug was compared with that of 
physical mixture of drug with all the excipients used in the study. The results showed that 
there was no drug-excipient interaction. The melting point was found to be 203
0
C and from 
the UV spectral analysis of the drug solution indicated that λmax value as 315 nm. 
               All the prepared ODT formulations were evaluated for physical characterstics, 
disintegration, In Vitro dissolution and stability study. 
               The hardness of formulations (F1-F9) were in the range of 3.13 – 3.4 Kg/cm2 
indicating good mechanical
 
strength and the thickness of formulations were in the range of 
5.13 – 5.72 mm. The weight variation and the friability were found within the official limits.  
                The In Vitro dispersion time of all the formulation was done and observed that 
there is decrease in the In Vitro dispersion time with the increase in the concentration of 
superdisintegrant. In Vitro dissolution study of all the formulations was carried out for 15 min 
and according to results formulation F3 was found as the best formulation, which showed 
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99.5% drug release at the end of 15 min. The selected formulation was subjected for the short 
term stability study for 60 days and the hardness, taste, friability, drug content and 
disintegration were observed and found no significant change in the results. 
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